GlobeImmune (GBIM) Inactive 10-K17 Mar 152014 FY Annual reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Feb. 27, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	GBIM
Entity Registrant Name	GLOBEIMMUNE INC
Entity Central Index Key	1245104
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,751,574
Entity Public Float		$29,844,264

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$16,812,459	$5,924,241
Other current assets	999,892	900,896
Total current assets	17,812,351	6,825,137
Property and equipment, net	455,768	492,802
Restricted cash	100,000	100,000
Total assets	18,368,119	7,417,939
Current liabilities:
Accounts payable	572,586	1,736,621
Accrued liabilities	1,259,332	920,962
Fair value of warrants		13
Deferred revenue	3,340,571	3,756,899
Total current liabilities	5,172,489	6,414,495
Other long-term liabilities	148,641	223,029
Deferred revenue	7,443,498	10,656,976
Fair value of warrants, net of current portion		1,564,928
Convertible promissory note		197,955
Total liabilities	12,764,628	19,057,383
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.001 par value. Authorized 100,000,000 shares; issued and outstanding 5,751,574 and 92,812 shares, respectively	5,752	93
Preferred stock, $0.001 par value. Authorized 5,000,000 shares; issued and outstanding 0 shares
Additional paid-in capital	228,302,479
Accumulated deficit	-222,704,740	-199,321,927
Total stockholders' equity (deficit)	5,603,491	-199,321,834
Total liabilities, redeemable, convertible preferred stock and stockholders' equity (deficit)	18,368,119	7,417,939
Series C
Current liabilities:
Redeemable, convertible preferred stock		67,548,103
Series D
Current liabilities:
Redeemable, convertible preferred stock		12,964,405
Series E
Current liabilities:
Redeemable, convertible preferred stock		23,482,780
Series A
Current liabilities:
Redeemable, convertible preferred stock		15,670,621
Series B
Current liabilities:
Redeemable, convertible preferred stock		$68,016,481

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	5,751,574	92,812
Common stock, shares outstanding	5,751,574	92,812
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series C
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	0
Convertible preferred stock, issued	0	31,147,071
Convertible preferred stock, outstanding	0	31,147,071
Convertible preferred stock, liquidation preference	$0	$67,948,149
Series D
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	0
Convertible preferred stock, issued	0	8,650,519
Convertible preferred stock, outstanding	0	8,650,519
Convertible preferred stock, liquidation preference	0	13,691,114
Series E
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	0
Convertible preferred stock, issued	0	11,665,019
Convertible preferred stock, outstanding	0	11,665,019
Convertible preferred stock, liquidation preference	0	23,535,170
Series A
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	0
Convertible preferred stock, issued	0	6,407,998
Convertible preferred stock, outstanding	0	6,407,998
Convertible preferred stock, liquidation preference	0	15,687,341
Series B
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	0	0
Convertible preferred stock, issued	0	28,699,551
Convertible preferred stock, outstanding	0	28,699,551
Convertible preferred stock, liquidation preference	$0	$68,056,641

Statements_of_Operations_and_C

Statements of Operations and Comprehensive Income and Loss (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue
Collaboration license and services	$4,426,561	$16,350,132	$12,641,606
Milestones		3,000,000	2,000,000
Manufacturing services	1,539,820	3,168,237
Total revenue	5,966,381	22,518,369	14,641,606
Research and development expenses:
Costs of collaboration license and services	3,452,392	5,856,013	10,033,040
Costs of manufacturing services	1,539,820	3,168,237
Research and development for proprietary programs	2,221,204	1,860,378	1,701,511
Total research and development	7,213,416	10,884,628	11,734,551
General and administrative	4,276,918	3,174,769	5,948,066
Depreciation and amortization	295,165	771,280	925,473
Total operating expenses	11,785,499	14,830,677	18,608,090
Income (loss) from operations	-5,819,118	7,687,692	-3,966,484
Change in value of warrants and put and call options, income (expense)	-1,903,446	1,842,557	1,951,490
Loss on extinguishment of convertible notes	-4,687,649
Interest expense	-3,890,662
Other income	39,949	62,215	250
Income (loss) before taxes	-16,260,926	9,592,464	-2,014,744
Income taxes		115,765
Net income (loss)	-16,260,926	9,476,699	-2,014,744
Preferred stock dividends and accretion of offering costs to redemption value	-7,173,901	-12,885,141	-12,104,251
Net loss applicable to common stockholders	($23,434,827)	($3,408,442)	($14,118,995)
Weighted average shares outstanding-basic and diluted	2,914,690	92,522	89,377
Net loss per share attributable to common stockholders-basic and diluted	($8.04)	($36.84)	($157.97)

Statement_of_Redeemable_Conver

Statement of Redeemable, Convertible Preferred Stock, and Stockholders' Deficit (USD $)	Total	Common stock	Additional paid-in capital	Accumulated Deficit	Redeemable, convertible Series A through E preferred stock
Beginning balance at Dec. 31, 2011	($182,396,638)	$88		($182,396,726)	$162,637,710
Beginning balance (shares) at Dec. 31, 2011		87,864			86,538,194
Accretion of offering costs	-526,957			-526,957	526,957
Estimated fair value of options for common stock issued for services	66,731		66,731
Accretion of preferred stock to redemption value	-11,577,294		-390,722	-11,186,572	11,577,294
Share-based compensation	302,449		302,449
Exercise of Series C preferred stock warrants					55,288
Exercise of Series C preferred stock warrants (shares)					31,964
Exercise of options	21,546	4	21,542
Exercise of options (shares)	4,566	4,566
Net income (loss)	-2,014,744			-2,014,744
Ending balance at Dec. 31, 2012	-196,124,907	92		-196,124,999	174,797,249
Ending balance (shares) at Dec. 31, 2012		92,430			86,570,158
Accretion of offering costs	-526,957			-526,957	526,957
Estimated fair value of options for common stock issued for services	27,165		27,165
Accretion of preferred stock to redemption value	-12,358,184		-211,514	-12,146,670	12,358,184
Share-based compensation	182,550		182,550
Exercise of options	1,800	1	1,799
Exercise of options (shares)	382	382
Net income (loss)	9,476,699			9,476,699
Ending balance at Dec. 31, 2013	-199,321,834	93		-199,321,927	187,682,390
Ending balance (shares) at Dec. 31, 2013		92,812			86,570,158
Accretion of offering costs	-274,811			-274,811	274,811
Estimated fair value of options for common stock issued for services	-40,747		-40,747
Accretion of preferred stock to redemption value	-6,899,090		-52,014	-6,847,076	6,899,090
Share-based compensation	89,625		89,625
Exercise of options	37,788	8	37,780
Exercise of options (shares)	8,009	8,009
Net income (loss)	-16,260,926			-16,260,926
Conversion of preferred stock to common stock upon initial public offering	194,856,291	2,758	194,853,533		-194,856,291
Conversion of preferred stock to common stock upon initial public offering (shares)		2,757,825			-86,570,158
Issuance of 1,725,000 shares of common stock (net of offering costs of $2,630,141)	14,619,859	1,725	14,618,134
Issuance of 1,725,000 shares of common stock (net of offering costs of $2,630,141) (shares)		1,725,000
Conversion of convertible notes to common stock	11,679,280	1,168	11,678,112
Conversion of convertible notes to common stock (shares)		1,167,928
Conversion of preferred stock warrants to common stock warrants	7,118,056		7,118,056
Ending balance at Dec. 31, 2014	$5,603,491	$5,752	$228,302,479	($222,704,740)
Ending balance (shares) at Dec. 31, 2014		5,751,574

Statement_of_Redeemable_Conver1

Statement of Redeemable, Convertible Preferred Stock, and Stockholders' Deficit (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2014
Common stock issuance costs	$2,630,141

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net income (loss)	($16,260,926)	$9,476,699	($2,014,744)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	295,165	771,280	925,473
Share-based compensation	89,625	182,550	302,449
Stock-based payments for services	-40,747	27,165	66,731
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs	3,562,946	9,268
Noncash interest expense on convertible notes	330,664
Noncash expense (income) from change in valuation of warrants and put and call options	1,903,446	-1,842,557	-1,951,490
Loss on extinguishment of convertible notes	4,687,649
Gain on sale of property and equipment	-91,285
Changes in operating assets and liabilities:
Increase in other current assets	-98,996	-14,501	-464,418
Increase (decrease) in accounts payable	-1,164,035	-828,883	1,642,319
Increase (decrease in accrued liabilities)	338,370	-710,820	287,256
Decrease in deferred revenue	-3,629,806	-3,142,740	-11,725,373
Increase (decrease) in other long-term liabilities	26,834	4,266	-136,243
Net cash provided by (used in) operating activities	-10,051,096	3,931,727	-13,068,040
Cash flows from investing activities:
Purchase of property and equipment	-294,200	-12,234	-108,828
Sale of property and equipment	127,354
Net cash used in investing activities	-166,846	-12,234	-108,828
Cash flows from financing activities:
Proceeds from issuance of common stock from stock option exercises	37,788	1,800	21,546
Proceeds from exercise of warrants			3,659
Proceeds from issuance of convertible promissory notes	7,500,000
Convertible promissory notes issuance costs	-1,051,487
Proceeds from issuance of common stock	17,250,000
Common stock issuance costs	-2,630,141
Net cash provided by financing activities	21,106,160	1,800	25,205
Net increase in cash and cash equivalents	10,888,218	3,921,293	-13,151,663
Cash and cash equivalents, beginning of period	5,924,241	2,002,948	15,154,611
Cash and cash equivalents, end of period	16,812,459	5,924,241	2,002,948
Supplemental disclosures of noncash investing and financing activities:
Accretion of preferred stock (dividends)	6,899,090	9,268,638	9,268,638
Accretion of preferred stock (offering costs)	274,811	395,217	395,217
Fair value of warrants and put option issued in connection with convertible note payable	6,121,533
Fair value of warrants issued for debt issuance costs	876,778
Non-cash conversion of convertible promissory notes to common stock	8,226,658
Non-cash conversion of preferred stock to common stock	$194,856,289

Organization_and_Nature_of_Bus

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Business	(1)Organization and Nature of Business
	GlobeImmune, Inc. (the Company) was incorporated as Ceres Pharmaceuticals, Ltd. in Colorado on February 10, 1995. The Company changed its name to GlobeImmune, Inc. on May 26, 2001, and reincorporated in Delaware on June 5, 2002. The Company is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen ® platform. The Company has two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogens program targeting the brachyury protein. The Company has four product candidates in five ongoing clinical trials.
	The Company’s operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, more stringent regulatory environment, the need to retain key personnel and protect intellectual property, product liability, and the availability of additional capital financing on terms acceptable to the Company. Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, the Company is unable to accurately predict the timing or amount of future expenses or when, or if, it will be able to achieve or maintain profitability. Currently, the Company has no products approved for commercial sale, and to date it has not generated any product revenue. The Company has financed its operations primarily through the sale of equity securities, upfront payments pursuant to collaboration agreements, government grants and equipment financing. The size of the Company’s future net losses will depend, in part, on the rate of growth or contraction of expenses and the level and rate of growth, if any, of revenues. The Company’s ability to achieve profitability is dependent on its ability, alone or with others, to complete the development of its product candidates successfully, obtain the required regulatory approvals, manufacture and market its proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when the Company will achieve profitability.

Liquidity_Risks

Liquidity Risks	12 Months Ended
Liquidity Risks	Dec. 31, 2014
Risks And Uncertainties [Abstract]
Liquidity Risks	(2)Liquidity Risks
	The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of December 31, 2014 and 2013, the Company had an accumulated deficit of $222,704,740 and $199,321,927, respectively. The Company had net loss of $16,260,926, net income of $9,476,699 and net loss of $2,014,744 for the years ended December 31, 2014, 2013 and 2012, respectively, and net cash used in operating activities of $10,051,096, net cash provided by operating activities of $3,931,727 and net cash used in operating activities of $13,068,040 for the years ended December 31, 2014, 2013 and 2012, respectively. The Company anticipates that operating losses and net cash used in operating activities will continue over the next several years.
	The Company has historically financed its operations primarily through the sale of equity securities, payments pursuant to collaboration agreements, government grants and equipment financing. The Company will continue to be dependent upon such sources of funds until it is able to generate positive cash flows from its operations. The Company believes that its existing cash and cash equivalents as of December 31, 2014 will be sufficient to fund operations through at least January 1, 2016.
	The Company will be required to fund future operations through the sale of its equity securities, issuance of debt, potential milestone payments, if achieved, and possible future collaboration. There can be no assurance that sufficient funds will be available to the Company when needed from equity or convertible debt financings, that milestone payments will be earned or that future collaboration partnerships will be entered into. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require the Company to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to it or its stockholders than the Company would otherwise choose. These events could prevent the Company from successfully executing on its operating plan and could raise substantial doubt about the Company’s ability to continue as a going concern in future periods.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2014
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	-3	Summary of Significant Accounting Policies
	(a)	Use of Estimates in the Preparation of Financial Statements
	The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management of the Company to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated accrued expenses, the impairment of long-lived assets, the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock.
	(b)	Initial Public Offering
	The Company completed an initial public offering (IPO) on July 8, 2014. In the offering, we sold 1,725,000 shares of our common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses. Upon completion of the offering, all of our then outstanding preferred stock converted into 2,757,825 shares of our common stock in accordance with the terms of the preferred stock, all of our outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the 2013 Note and the 2014 Notes, described in note 6, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the 2013 Note upon such conversion and the warrants issued to the holders of the 2014 Notes become exercisable for 12,373 and 750,000 shares of common stock, respectively.
	(c)	Reverse Stock Split
	On April 25, 2014, the Company affected a 1-for-4.3 reverse stock split of the Company’s common stock after approval by the Company’s stockholders. In connection with the reverse stock split, the Company filed a Certificate of Amendment of its Restated Certificate of Incorporation with the Secretary of State of Delaware on April 25, 2014 affecting the reverse stock split. This reverse stock split has been reflected retroactively for all periods presented in the financial statements.
	(d)	Cash and Cash Equivalents
	The Company considers all highly liquid instruments purchased with original maturity dates of 90 days or less to be cash equivalents. The Company places its temporary cash investments on deposit with financial institutions it believes to be of high quality. Cash equivalents have maturities of 90 days or less, and their carrying amounts approximate fair value.
	(e)	Concentrations of Credit Risk
	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio, and making investments with maturities that maintain safety and liquidity. At December 31, 2014, 2013 and 2012, the Company’s cash equivalents were with money market funds that invest in securities issued by the U.S. Treasury.
	(f)	Property and Equipment
	Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and major additions, replacements, and improvements are capitalized. Leasehold improvements are amortized over the shorter of the related lease term or the estimated useful life.


	Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows:



	Furniture and fixtures		7 years
	Leasehold improvements		Lesser of useful life or life of the lease
	Laboratory machinery and equipment		5 years
	Computer equipment		3 years
	The cost of assets sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected in the statements of operations and comprehensive income and loss in the period in which such sale or disposition occurs. Depreciation and amortization expense for the years ended December 31, 2014, 2013 and 2012 was $295,165, $771,280 and $925,473, respectively.
	(g)	Impairment of Long-Lived Assets
	The Company reviews its long-lived assets, consisting of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from future undiscounted cash flows. Impairment losses are recorded for the difference between the carrying value and the estimated fair value of the long-lived assets. The Company has not yet generated consistent positive cash flows on an annual basis, and such positive cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired.
	(h)	Restricted Cash
	As of December 31, 2014 and 2013, restricted cash, classified as long-term assets in the accompanying balance sheets consisted of a security deposit for the lease agreement for the corporate headquarters building.
	(i)	Accrued Liabilities
	The Company makes estimates of its accrued expenses by identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of the Company’s service providers invoice it monthly in arrears for services performed. Examples of estimated accrued expenses include:
	·	fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials;
	·	fees owed to investigative sites in connection with clinical trials;
	·	fees owed to contract manufacturers in connection with the production of clinical trial materials;
	·	fees owed for professional services;
	·	property taxes; and
	·	unpaid salaries, wages, and benefits.
	Accrued liabilities consisted of the following as of:

			Year ended December 31,
			2014			2013
	Accrued compensation			578,091		$	278,108
	Accrued clinical trial holdbacks			32,385			126,455
	Income taxes		—				115,765
	Other			648,856			400,634
	Total Accrued Liabilities			1,259,332		$	920,962

	As of December 31, 2014 and 2013, accrued liabilities included $32,385 and $126,455 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by the Company.
	(j)	Deferred Revenue
	The Company records amounts received but not earned under its collaboration agreements as deferred revenue, which are then classified as either current or long-term in the accompanying balance sheets based on the period during which they are expected to be recognized as revenue.
	(k)	Stock-Based Compensation
	The Company accounts for stock compensation pursuant to ASC Topic 718, Compensation-Stock Compensation. The Company applies the straight-line attribution method and, accordingly, amortizes the fair value of each option over the requisite service period through the last separately vesting portion of the award. Employee stock options granted by the Company are generally structured to qualify as “incentive stock options” (ISOs). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise, or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition occurs.
	The Company accounts for stock options issued to nonemployees in accordance with the provisions of ASC Topic 718 and ASC Subtopic 505-50, Equity-Based Payments to Nonemployees , which requires valuing the stock options using a Black-Scholes option pricing model and remeasuring such stock options to their current fair value until the performance date has been reached.
	(l)	Income Taxes
	The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes, which requires the use of the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for operating loss and tax credit carryforwards. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. As of December 31, 2014 and 2013, the Company has no unrecognized uncertain tax positions.
	(m)	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accrued liabilities and accounts payable, approximate fair value due to their short-term maturities. The carrying amount of the convertible note payable approximated its fair value as its terms were comparable to what would be included in similar debt instruments.
	The Company accounted for its preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and classified warrants for redeemable preferred stock as liabilities. The warrants were reported as short-term or long-term liabilities, depending on their remaining term, at their estimated fair value at December 31, 2013, and any changes in fair value are reflected in changes in value of warrants. The preferred stock warrant liability was reclassified to additional paid-in capital upon the closing of our IPO in July 2014.
	The fair value of all the outstanding warrants at July 8, 2014 (the close of our IPO) and December 31, 2013 was $7,118,054 and $1,564,941, respectively (see note 7).
	(n)	Segment Information
	The Company operates in one segment, which is the business of developing and commercializing various biopharmaceutical products.
	(o)	Research and Development Expenses
	During 2014, 2013 and 2012, the Company incurred $7,213,416, $10,884,628 and $11,734,551, respectively, in expenses relating to research and development. Research and development costs are expensed as incurred and include costs of collaboration license and services, cost of manufacturing services and research and development for proprietary programs. These costs consist primarily of salaries, supplies, and contract services relating to the development of new products and technologies.
	The Company contracts with third parties to perform a range of clinical trial activities in the ongoing development of its product candidates. The terms of these agreements vary and may result in uneven payments. Payments under these contracts depend on factors such as the progress toward achievement of certain defined milestones, the successful enrollment of patients, and other events.
(p)	Revenue Recognition
In 2014, 2013 and 2012, the Company’s revenue was in the form of upfront fees derived from the discovery, development and commercialization of multiple product candidates based on targeted molecular immunotherapy for the treatment of cancer and infectious diseases and fees for manufacturing services for the Company’s collaborators. The Company’s agreements with its collaborators include fees based on a nonrefundable upfront fee, nonrefundable milestone payments that are triggered upon achievement of specific development or regulatory goals, and future royalties on sales of products that result from the collaboration (see note 8(a) and 8(b)) and fees for manufacturing services.
The Company recognizes revenue in accordance with ASC Topic 605 Revenue Recognition (ASC 605). ASC 605 establishes four criteria, each of which must be met, in order to recognize revenue related to the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable, and (d) collectability is reasonably assured.
The Company evaluates the deliverables under our multiple-element arrangements to determine if they meet the separation criteria in ASC 605-25 and have stand-alone value. The Company allocates revenue to each identified deliverable based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, otherwise known as the relative selling price method. The allocated consideration for each deliverable is then recognized over the related obligation period for that deliverable. The Company treats deliverables in an arrangement that do not meet the separation criteria as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.
The Company recognizes revenue from nonrefundable upfront payments over the estimated term of performance under the agreements. Since the term is not specifically identifiable in the agreements, management has estimated the performance terms based on the likelihood and forecasted achievement of development commitments, and other significant commitments of the Company. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying balance sheets.
Management evaluates the likely performance period under its collaboration agreements on a periodic basis. If there are changes to the estimated performance periods as a result of the outcome of certain events, the period over which the nonrefundable upfront payments are recognized will be adjusted prospectively. The events that will impact the estimation of the performance period include, among others, the success of the drug candidate programs and the likelihood of the collaborator exercising their options under the collaboration agreement.
The Company’s collaboration agreements provide for milestone payments and royalties on future sales. In accordance with the milestone method, each substantive milestone payment is recognized as revenue when the specific milestone is achieved and royalties are recorded when earned.
Revenue recognition related to upfront payments and to milestone payments could be accelerated in the event of early termination of drug programs or, alternatively, decelerated if programs are extended. As such, while changes to such estimates have no impact on its reported cash flows, the Company’s reported revenue is significantly influenced by its estimates of the period over which its obligations are expected to be performed.
The Company categorizes its revenues into collaboration license and services, milestones and manufacturing services, substantially all of which come from its collaboration partners.
In 2013, the Company received a $4,000,000 Research Project Grant by the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institute of Health, or NIH, to support the development of Tarmogen immunotherapy product candidates to treat and prevent tuberculosis infection. This work for this grant will be performed and reimbursed over four years. The Company recognizes revenue from this grant as work is performed.
(q)	Net Loss per Share
Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.
The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders:

		Years ended December 31,
		2014			2013			2012
Net loss per share:
Numerator:
Net loss attributable to GlobeImmune, Inc. common			(23,434,827	)		(3,408,442	)		(14,118,995	)
stockholders			(23,434,827	)		(3,408,442	)		(14,118,995	)
Denominator:
Weighted-average common shares used in computing			2,914,690			92,522			89,377
net loss per share of common stock - basic and diluted			2,914,690			92,522			89,377
Net loss per share of common stock attributable to			(8.04	)		(36.84	)		(157.97	)
GlobeImmune, Inc. stockholders - basic and diluted			(8.04	)		(36.84	)		(157.97	)


The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive:

		Years ended December 31,
		2014			2013			2012

Weighted-average convertible preferred stock upon			1,428,024			2,757,825			2,757,113
conversion to common stock (as converted basis) *			1,428,024			2,757,825			2,757,113

Weighted-average warrants to purchase convertible			411,303			107,057			108,986
preferred stock as converted basis) *			411,303			107,057			108,986

Outstanding stock options and warrants to purchase			219,180			229,494			376,880
common stock at period-end)			219,180			229,494			376,880

Weighted-average convertible promissory note upon			509,947			6,921			—
conversion to common stock (as converted basis)			509,947			6,921			—
Total			2,568,454			3,101,297			3,242,979



*	The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.
(r)	Recently Issued Accounting Standards
On May 28, 2014, the FASB issued guidance that requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. The new standard is effective for the Company on September 1, 2017, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that this new guidance will have on its consolidated financial statements and related disclosures. The Company has not selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and provide related disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January 1, 2017 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, the Company has elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. This election is irrevocable.
(s)	Fair Value Measurements
In general, asset and liability fair values are determined using the following categories:
Level 1– inputs utilize quoted prices in active markets for identical assets or liabilities.
Level 2– inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
Level 3– inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own assumptions about the assumptions that a market participant would use.
The Company’s financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2014 and 2013 approximates fair value based on quoted prices in active markets, or Level 1 inputs. The carrying amount of outstanding warrants and put options as of December 31, 2013 approximates fair value based on unobservable inputs, or Level 3 inputs, using assumptions made by the Company, including pricing, volatility, and expected term. There were no transfers between levels for the years ended December 31, 2014, 2013 and 2012.
Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2014 and 2013:

Description		December 31,			Quoted			Significant			December 31,		Quoted		Significant
		2014			prices in			unobservable			2013		prices in		unobservable
					active			inputs					active		inputs
					markets for			(Level 3)					markets for		(Level 3)
					identical								identical
					assets								assets
					(Level 1)								(Level 1)
Assets measured at fair value:
Money market investments (included in cash			20,173			20,173			—			20,672		20,672		—
and cash equivalents)			20,173			20,173			—			20,672		20,672		—
Liabilities measured at fair value:
Warrants (included in fair value of warrants)			—			—			—			1,564,941		—		1,564,941
Put and call options (included in fair value of			—			—			—			101,222		—		101,222
put and call options and other long-term
liabilities)

A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:

		Warrants			Put and call options
Balance of liability at December 31, 2011			(5,304,530	)	—
Transfer of fair value of warrants to preferred stock			51,629
upon exercise			51,629
Income included in net loss:
Income due to change in fair value			1,951,490		—

Balance of liability at December 31, 2012			(3,301,411	)	—
Issuance of warrants in connection with convertible			(106,087	)	—
promissory notes			(106,087	)	—
Issuance of put options in connection with convertible		—				(101,222	)
promissory notes		—				(101,222	)
Income included in net income:
Income due to change in fair value			1,842,557		—

Balance of liability at December 31, 2013		$	(1,564,941	)		(101,222	)
Issuance of warrants in connection with convertible			(5,331,175	)	—
promissory notes			(5,331,175	)	—
Issuance of put and call options in connection with		—				(1,667,136	)
convertible promissory notes		—				(1,667,136	)
Transfer to additional paid-in capital upon completion of			7,118,054			3,449,866
initial public offering			7,118,054			3,449,866
Loss included in net loss:
Loss due to change in fair value			(221,938	)		(1,681,508	)
Balance of liability at December 31, 2014		$	—			—

Gains (losses) included in net income and loss for the years ended December 31, 2014, 2013 and 2012 are reported in change in value of warrants.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	12 Months Ended
Cash and Cash Equivalents	Dec. 31, 2014
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	-4	Cash and Cash Equivalents
	The following is a summary of cash and cash equivalents and their fair values at:

			Amortized		Unrealized		Unrealized		Fair market
			cost		gains		losses		value
	31-Dec-13
	Cash		$	5,903,569	$	—	$	—	$	5,903,569
	Money market funds			20,672		—		—		20,672
	Total at December 31, 2013		$	5,924,241	$	—	$	—	$	5,924,241
	31-Dec-14
	Cash		$	16,792,286	$	—	$	—	$	16,792,286
	Money market funds			20,173		—		—		20,173
	Total at December 31, 2014		$	16,812,459	$	—	$	—	$	16,812,459

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Property and Equipment	-5	Property and Equipment
	Property and equipment consist of the following at:

			Year ended December 31,
			2014			2013
	Furniture and fixtures			212,471			212,471
	Leasehold improvements			7,617,934			7,563,511
	Laboratory equipment			3,819,740			3,726,953
	Computer and office equipment			617,264			595,872
				12,267,409			12,098,807
	Less accumulated depreciation			(11,811,641	)		(11,606,005	)
				455,768			492,802

Convertible_Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Convertible Notes	-6	Convertible Notes
	2013 Notes
	In November 2013, we entered into an unsecured convertible promissory note, or the 2013 Note, with a service provider, or the Holder, in settlement of $391,730 of accounts payable. The 2013 Note bears an interest rate of 8.0%, has a term of three years and can be prepaid at any time. The 2013 Note and unpaid accrued interest converted upon the completion of our initial public offering into common stock at a price per share equal to 80% at which our common stock was first offered to the public. Upon completion of our initial public offering, we issued to the holder of the 2013 Note a warrant, equal to 30% of the principal balance of the 2013 Note, to purchase common stock for 10 years with an exercise price equal to the IPO price.
	We recorded the proceeds from the Note based on the fair value of the warrants ($106,087), put option embedded in the 2013 Note ($101,222) and the 2013 Note and, as such, recorded a debt discount of $207,309 for the allocated value of the warrants and put option. The debt discount was being amortized to interest expense over the term of the 2013 Note. Amortization of $9,268 and $35,749 was recorded in the years ended December 31, 2013 and 2014, respectively, and the unamortized balance of the debt discount was $198,041 as of December 31, 2013.
	On July 8, 2014 we completed our initial public offering and the 2013 Note converted into 51,556 shares of common stock at $8.00 per share. The carrying amount of the debt for accounting purposes was $352,986, which includes accrued interest of $20,718, through the conversion date. We recorded a loss upon the extinguishment of $162,574, equal to the difference between the carrying value and the fair value of the common stock which extinguished the 2013 Note. Upon the conversion of the 2013 Note, pursuant to the 2013 Note’s terms, we issued to the holder of the 2013 Note a warrant exercisable for 12,373 shares of our common stock at an exercise price of $10.00 per share.
	The estimated fair value of the 2013 Note as of December 31, 2013 approximated its carrying value.
	2014 Convertible Notes
	In January and February 2014, we entered into unsecured convertible notes, the 2014 Notes, with various holders for a total aggregate principal amount of $7,500,000. The 2014 Notes bore an interest rate of 10.0% and had a maturity date of January 31, 2015. Upon completion of our IPO the outstanding principal amount of the 2014 Notes, and any unpaid accrued interest thereon, converted into common stock at a price equal to 70% of the price at which our common stock was first offered to the public.
	The holders of the 2014 Notes received warrants, equal to 100% of the principal amount of the 2014 Notes to purchase equity securities of us for a five-year period. As a result of our initial public offering, the warrants are exercisable into common stock with an exercise price equal to the price at which our common stock was first offered to the public.
	We recorded the proceeds from the 2014 Notes based on the fair value of the warrants ($4,454,397), the net of the put and call option embedded in the 2014 Notes ($1,667,136) and the 2014 Notes. As such, we recorded a debt discount of $6,121,533 from the allocated value of the warrants and the put and call options. Amortization of $2,682,285 was recorded in the year ended December 31, 2014.
	We incurred $1,928,265 of debt issuance costs related to the 2014 Notes. Included in the debt issuance costs were warrants issued to the placement agent that had an estimated value of $876,778 at issuance. Amortization of $844,912 was recorded in the year ended December 31, 2014.
	On July 8, 2014 we completed an IPO and the 2014 Notes converted into 1,116,372 shares of common stock at a conversion price of $7.00 per share. The carrying amount of the debt for accounting purposes was $6,638,645, which included accrued interest of $314,210, through the conversion date. We recorded a loss upon the extinguishment of $4,525,075, equal to the difference between the carrying value and the fair value of the common stock which extinguished the 2014 Notes. Upon the conversion of the 2014 Notes, pursuant to the terms thereof, we issued to the holders of the 2014 Notes warrants exercisable for 750,000 shares of our common stock at an exercise price of $10.00 per share.

Redeemable_Convertible_Preferr

Redeemable, Convertible Preferred Stock and Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Redeemable, Convertible Preferred Stock and Stockholdersb Equity	-7	Redeemable, Convertible Preferred Stock and Stockholders’ Equity
	(a)	Stockholders Agreement
	Prior to the IPO all stockholders were party to a stockholders agreement that significantly restricted the transferability of shares of the Company’s capital stock and provided for other corporate governance matters. The stockholders agreement also gave the Company right of first offer on the purchase of shares from stockholders.
	(b)	Series C Redeemable, Convertible Preferred Stock
	In the third quarter of 2007, the Company issued 28,482,897 shares of Series C redeemable, convertible (Series C) preferred stock for cash of $1.445 per share. Each share converted into shares of common stock on a 31.39-for-one basis upon closing of the IPO. Holders of Series C preferred stock possessed certain rights, including, among others, preference in liquidation (including a sale of the Company), antidilution protection, and preemptive rights relative to holders of common stock, Series A redeemable, convertible (Series A) preferred stock and Series B redeemable, convertible (Series B) preferred stock. In the event of a liquidation event, holders of Series C preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends. Each holder of Series C preferred stock was entitled to receive, if and when declared, payment of an equivalent per share dividend based on the number of common shares into which each share of preferred stock is convertible, as of the date of declaration. The rate of conversion of Series C preferred stock into common stock was to be adjusted in the event the Company issued dilutive shares of common stock according to a formula defined in the Company’s Restated Certificate of Incorporation. Holders of Series C preferred stock were entitled to vote as though the preferred stock was converted into common stock. Holders of Series C preferred stock were entitled to present a redemption request to the Company in January 2015 for redemption of 25% of their total cumulative holdings per year, in the amount of the original purchase price plus 7% per annum compounded annually plus accrued but unpaid dividends.
	During March and April 2009, the Company issued $2,999,989 of unsecured convertible promissory notes at an interest rate of 8.0%. Upon the closing of the sale of Series D redeemable, convertible (Series D) preferred stock, these notes and the accrued interest converted to 2,632,210 shares of Series C preferred stock at $1.156 per share. The existing stockholders waived their antidilution rights as part of the issuance of the notes. In connection with the issuance and conversion of these unsecured convertible promissory notes, the Company issued warrants to purchase 622,826 shares of Series C preferred stock for $1.445 per share. At the date of issuance, the Company estimated the value of the warrants at $603,767 using the Black-Scholes option pricing model, and the following assumptions: 10-year term, 87.5% volatility, and a risk-free interest rate of 2.87%.
	During 2012, a warrant for 158,129 shares was exercised for 29,432 shares of Series C preferred stock. The fair value of the warrant at the exercise date was reclassified to redeemable convertible preferred stock Series C.
	During 2012, a warrant for 2,532 shares was exercised for Series C preferred stock at an exercise price of $1.445 per warrant. The total proceeds of $3,659 were recorded as redeemable convertible preferred stock Series C and the fair value of the warrant at the exercise date was reclassified to redeemable convertible preferred stock Series C.
	(c)	Series D Redeemable, Convertible Preferred Stock
	In May 2009, the Company issued 8,650,519 shares of Series D preferred stock for $10,000,000 at $1.156 per share with Celgene. In connection with the closing, the existing stockholders waived their antidilution rights. Each share converted into shares of common stock on a 31.39-for-one basis upon the closing of the IPO. Holders of Series D preferred stock possessed certain rights, including, among others, preference in liquidation (including a sale of the Company), antidilution protection, and preemptive rights relative to holders of common stock, Series A preferred stock and Series B preferred stock. In the event of a liquidation event, holders of Series D preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends. Each holder of Series D preferred stock was entitled to receive, if and when declared, payment of an equivalent per share dividend based on the number of common shares into which each share of preferred stock is convertible, as of the date of declaration. The rate of conversion of Series D preferred stock into common stock was to be adjusted in the event the Company issued dilutive shares of common stock according to a formula defined in the Company’s Restated Certificate of Incorporation. Holders of Series D preferred stock were entitled to vote as though the preferred stock was converted into common stock. Holders of Series D preferred stock were entitled to present a redemption request to the Company in January 2015 for redemption of 25% of their total cumulative holdings per year, in the amount of the original purchase price plus 7% per annum compounded annually plus accrued but unpaid dividends.
	In connection with the closing, the Company also issued warrants to purchase 2,076,125 shares of Series C preferred stock for $1.445 per share. The warrants were accounted for as a preferred stock issuance cost, with the estimated fair value of $2,052,662 determined using the Black-Scholes option pricing model, and the following assumptions: 10-year term, 90.5% volatility, and a risk-free interest rate of 3.29%.
	(d)	Series E Redeemable, Convertible Preferred Stock
	In January 2010, the Company issued 11,665,019 shares of Series E redeemable, convertible (Series E) preferred stock for approximately $17,999,124 at $1.543 per share. Each share converted into shares of common stock on a 31.39-for-one basis upon the closing of the IPO. Holders of Series E preferred stock possessed certain rights, including, among others, preference in liquidation (including a sale of the Company), antidilution protection, and preemptive rights relative to holders of common stock, Series A preferred stock and Series B preferred stock. In the event of a liquidation event, holders of Series E preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends. Each holder of Series E preferred stock was entitled to receive, if and when declared, payment of an equivalent per share dividend based on the number of common shares into which each share of preferred stock is convertible, as of the date of declaration. The rate of conversion of Series E preferred stock into common stock was to be adjusted in the event the Company issued dilutive shares of common stock according to a formula defined in the Company’s Restated Certificate of Incorporation. Holders of Series E preferred stock were entitled to vote as though the preferred stock was converted into common stock. Holders of Series E preferred stock were entitled to present a redemption request to the Company in January 2015 for redemption of 25% of their total cumulative holdings per year, in the amount of the original purchase price plus 7% per annum compounded annually plus accrued but unpaid dividends.
	(e)	Series A Redeemable, Convertible Preferred Stock
	In June and October 2003, the Company issued 3,999,999 shares of Series A preferred stock for cash of $1.25 per share and the conversion of $100,000 in aggregate principal amount of convertible promissory notes and $1,532 in aggregate accrued interest thereon. In September 2004, the Company issued 2,399,999 shares of Series A preferred stock for cash of $1.25 per share. Each share converted into shares of common stock on a 31.39-for-one basis upon closing of the IPO. Holders of Series A preferred stock possessed certain rights including, among others, preference in liquidation (including a sale of the Company), antidilution protection, and preemptive rights relative to holders of common stock. In the event of a liquidation event, holders of Series A preferred stock shall be entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends. Each holder of Series A preferred stock was entitled to receive, if and when declared, payment of an equivalent per share dividend based on the number of common shares into which each share of preferred stock is convertible, as of the date of declaration. The rate of conversion of Series A preferred stock into common stock was to be adjusted in the event the Company issued dilutive shares of common stock according to a formula defined in the Company’s Restated Certificate of Incorporation. Holders of Series A preferred stock were entitled to vote as though the preferred stock was converted into common stock. Holders of Series A preferred stock were entitled to present a redemption request to the Company in January 2015 for redemption of 25% of their total cumulative holdings per year, in the amount of the original purchase price plus 7% per annum compounded annually plus accrued but unpaid dividends.
	During 2010, a warrant for 8,000 shares was exercised for Series A preferred stock at an exercise price of $1.25 per warrant. The total proceeds of $10,000 was recorded as redeemable convertible preferred stock Series A and the fair value of the warrant at the exercise date was reclassified to redeemable convertible preferred stock Series A.
	(f)	Series B Redeemable, Convertible Preferred Stock
	During 2005, the Company closed on several issuances of Series B preferred stock for cash and convertible promissory notes payable at $1.338 per share as follows:

						Amount			Shares
	Initial closing		Jun-05			25,050,000			18,721,973
	Second closing		Jul-05			3,500,001			2,615,845
	Third closing		August 2005			4,750,000			3,550,073
	Fourth closing		September 2005			1,000,000			747,384
	Fifth closing		Sep-05			2,000,000			1,494,768
	Sixth closing		Oct-05			1,000,001			747,385
	Final closing		Dec-05			1,100,001			822,123
						38,400,003			28,699,551
	The initial closing in June 2005 included the conversion of $2,750,000 in aggregate principal amount of convertible promissory notes and $50,342 of aggregate accrued interest thereon. Each share of Series B converted into shares of common stock on a 31.39-for-one basis upon closing of the IPO. Holders of Series B preferred stock possessed certain rights, including, among others, preference in liquidation (including a sale of the Company), antidilution protection, and preemptive rights relative to holders of common stock. In the event of a liquidation event, holders of Series B preferred stock shall be entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends. Each holder of Series B preferred stock was entitled to receive, if and when declared, payment of an equivalent per share dividend based on the number of common shares into which each share of preferred stock is convertible, as of the date of declaration. The rate of conversion of Series B preferred stock into common stock was to be adjusted in the event the Company issues dilutive shares of common stock according to a formula defined in the Company’s Restated Certificate of Incorporation. Holders of Series B preferred stock were entitled to vote as though the preferred stock was converted into common stock. Holders of Series B preferred stock were entitled to present a redemption request to the Company in January 2015 for redemption of 25% of their total cumulative holdings per year, in the amount of the original purchase price plus 7% per annum compounded annually plus accrued but unpaid dividends.
	(g) Preferred Stock
	The Board of Directors may issue Preferred Stock in one or more series and determine the voting power, designation, preferences and any other rights as may be permitted by Delaware General Corporation Law. On July 8, 2014, the Company authorized 5,000,000 shares of preferred stock with a $0.001 par value, of which no shares were issued or outstanding as of December 31, 2014.
	(h)	Stock Option Plan
	During 2002, the Company established a stock option plan (the 2002 Option Plan) providing for the grant of options to purchase common shares to outside directors, executives, certain key employees, and consultants.
	In April 2014, the Company adopted the 2014 Equity Incentive Plan (2014 EIP) and reserved 393,358 shares of common stock for issuance under the plan. The 2014 EIP is the successor to and continuation of the 2002 Option Plan. The options still outstanding under the 2002 Option Plan will continue to be governed by their existing terms, but any shares subject to outstanding options granted under the 2002 Option Plan that would for any reason subsequently return to the share reserve of the 2002 Option Plan under its terms, will not return to the share reserve of the 2002 Option Plan but will become available for issuance pursuant to awards granted under the 2014 EIP. The number of shares of common stock reserved for issuance under the 2014 EIP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the lesser of 4% of the total number shares of our common stock outstanding on the immediately preceding December 31, or a lesser amount of shares determined by our Board of Directors.
	In April 2014, the Company adopted the 2014 Employee Stock Purchase Plan (2014 ESPP) and reserved 201,163 shares of common stock for issuance under the plan. The number of shares of common stock reserved for issuance under the 2014 ESPP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the least of (i) 1% of the total number of shares of our common stock outstanding on the immediately preceding December 31; (ii) 402,326 shares of common stock; or (iii) a lesser amount of shares determined by our Board of Directors.
	As of December 31, 2014, there were 841,580 shares authorized, of which 601,313 , were available for future issuance under the 2014 EIP. All of the foregoing shares will become eligible for sale in the public market to the extent permitted by any applicable vesting requirements, the lock-up agreements and Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act.
	Pursuant to the evergreen provisions of the 2014 ESPP and 2014 EIP, on January 1, 2015, common stock reserved for issuance under the 2014 ESPP automatically increased 57,515 shares to 258,678 shares of common stock and common stock reserved for issuance under the 2014 EIP automatically increased 230,062 shares to 1,071,642 shares of common stock.
	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for employee grants and used the following assumptions to obtain the weighted average grant date fair values:

			Year Ended December 31,
			2014				2013 (a)				2012
	Risk-free interest rate			1.82%				—				1.30%
	Expected life (in years)			6				—			5.8 - 6.0
	Expected volatility			95.70%				—			90.9% - 91.2%

		(a)There were no stock options granted in 2013.
	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for nonemployee grants and used the following assumptions to estimate fair value each respective year:

			Year Ended December 31,
			2014		2013		2012
	Risk-free interest rate		2.8% -3.0%		1.8% -2.7%		1.4% -2.2%
	Expected life (in years)		10		10		10
	Expected volatility		85.2% -85.4%		82.6% -85.1%		83.3% -85.2%

	The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Since the Company has a limited history of stock activity, expected volatility is based on historical data from several public companies similar in size and nature of operations to the Company. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for employee options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted. Since the Company has limited employee share option exercises, the expected term was determined using the average of the vesting periods and expirations.
	Prior to the closing of the IPO, to value its common stock for measuring equity based awards, the Company used a combination of the option pricing method and the Probability-Weighted Expected Return Method (“PWERM”) as outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (AICPA Practice Aid). The option pricing method treats common stock and preferred stock as call options on a subject company’s equity value, with exercise prices based on the liquidation preference of the preferred stock. The model estimates the fair value of each class of securities as a function of the current estimated fair value of the company. The characteristics of each class of stock are examined, including: (1) the conversion ratio; (2) the liquidation preferences assigned to the preferred classes of stock; and (3) the exercise price for all outstanding options and warrants. Under this method, value is allocated to common shares only in circumstances where the total equity value exceeds the liquidation rights associated with the preferred shares. The option-pricing method provides the stockholder the right, but not the obligation, to buy the underlying net assets at a predetermined price or “strike” price. The strike price is determined by analyzing the break points at which value would be allocated to each class of stock, based on the distribution characteristics associated with the equity. The PWERM analyzes the returns afforded to common equity holders under multiple future scenarios. Under the PWERM, share value is based upon the probability-weighted present value of expected future net cash flows (distributions to shareholders), considering each of the possible future events and giving consideration to the rights and preferences of each share class. While this method relies on certain key assumptions, it is best used when the range of possible future outcomes and the corresponding time frames are highly uncertain.
	Share-based compensation expense is recognized net of estimated pre-vesting forfeitures, which results in recognition of expense on options that are ultimately expected to vest over the expected option term. Forfeitures are estimated at the time of grant using actual historical forfeiture experience and are revised in subsequent periods if actual forfeitures differ from those estimates.
	The following table summarizes common stock option and warrant activities for common stock options and warrants issued to employees, directors, and consultants:

											Weighted
							Weighted				average
			Number of				average				remaining
			common stock				exercise				contractual
			options				price				term (years)
Outstanding at December 31, 2011			362,274				7.08
Granted			27,105				18.24
Exercised			(4,566	)			4.73
Canceled			(7,933	)			9.15
Outstanding at December 31, 2012			376,880				7.87
Exercised			(382	)			4.73
Canceled			(147,004	)			7.82
Outstanding at December 31, 2013			229,494				7.9
Granted			7,279				15.1
Exercised			(8,009	)			4.73
Canceled			(9,584	)			5.86
Outstanding at December 31, 2014			219,180				8.35				3.8
Exercisable at December 31, 2014			207,958				7.92				3.6

The following table summarizes information about stock options issued to employees, directors, and consultants that is outstanding at December 31, 2014:

		Common stock options								Common stock options
		outstanding								exercisable
						Weighted
						average							Weighted
						remaining							average
		Number				contractual				Number			exercise
Exercise price		outstanding				life (years)				exercisable			price
$ 4.73			56,175				1.34				56,175		$	4.73
5.04			4,820				2.34				4,820			5.04
5.98			67,575				3.17				67,575			5.98
6.93			14,882				4.25				14,882			6.93
8.52			6,971				4.75				6,971			8.52
10.07			2,814				6.21				2,814			10.07
12.56			41,464				5.61				41,464			12.56
15.10			7,279				9.2				—			15.1
18.24			17,200				7.24				13,257			18.24
			219,180								207,958

The weighted average grant date fair value of options granted during the years ended December 31, 2014 and 2012 was $11.66 and $13.55 per share, respectively. The total grant date fair value of options that vested during 2014, 2013 and 2012 was $72,095, $193,828 and $308,803, respectively. The total intrinsic value, or the difference between the aggregate exercise price and the aggregate fair market price on the day of exercise, of options exercised during the years ended December 31, 2014, 2013 and 2012 was $60,940, $1,560 and $139,620, respectively. The total intrinsic value of options outstanding as of December 31, 2014 and 2013 was $286,299 and $1,703,515, respectively. The total intrinsic value of options exercisable as of December 31, 2014 and 2013 was $286,299 and $1,696,012, respectively. As of December 31, 2014 and 2013, the Company had unrecognized stock-based compensation of $79,145 and $60,510, respectively, related to nonvested stock options, which is expected to be recognized over an estimated weighted average period of 2.2 and 1.8 years, respectively.

The Company’s net loss for the years ended December 31, 2014, 2013 and 2012 includes $48,878, $209,715, $369,180 respectively, of stock-based compensation costs. Stock-based compensation included in the Company’s statements of operations and comprehensive income and loss for the years ended December 31, 2014, 2013 and 2012 was $8,919, $47,082 and $143,169 in research and development expenses and $39,959, $162,633, $226,011 in general and administrative expenses, respectively.
The Company did not recognize a tax benefit from share-based compensation expense because the Company has concluded that it is not more likely than not that the related deferred tax assets, which have been reduced by a full valuation allowance, will be realized.
(i)	Warrants
The Company had the following preferred stock warrants that vested upon issuance outstanding as of December 31, 2013 and July 8, 2014 (the close of the IPO). Also included below are the Black-Scholes assumptions used to estimate the fair value of the warrants:

																Issuance of
		2004				Convertible				2006			Convertible			Series D			Total		Total
		Financing				promissory				Financing			promissory			preferred			Long-		Short-
Warrants issued in connection with		agreement				notes				agreement			notes			stock			term		term
Issue date		March 2004				June 2005				April 2006			May 2009			May 2009
Redeemable, convertible preferred stock		Series A				Series B				Series B			Series C			Series C
underlying the warrant		Series A				Series B				Series B			Series C			Series C
Number of warrants			22,000				411,060				179,372			622,826			2,076,125
Exercise price		$	1.25			1.338				1.338			1.445			1.445
Black-Scholes assumptions as of December 31,
2012
Remaining term (years)		1.2				2.5				3.3			6.4			6.4
Estimated volatility			83	%			86.5	%			85.5	%		92	%		92	%
Risk-free interest rate			0.16	%			0.31	%			0.35	%		0.92	%		0.92	%
Number of warrants remaining			22,000				411,060				179,372			620,294			2,076,125
Estimated fair value at December 31, 2012		$	2,837				100,270				52,680			723,631			2,421,993			3,301,411		—
Black-Scholes assumptions as of December 31,
2013
Remaining term (years)		0.2				1.5				2.3			5.4			5.4
Estimated volatility			61	%			66.5	%			84.5	%		97	%		97	%
Risk-free interest rate			0.07	%			0.24	%			0.52	%		1.58	%		1.58	%
Number of warrants remaining			22,000				411,060				179,372			620,294			2,076,125
Estimated fair value at December 31, 2013		$	13				28,098				32,735			321,603			1,076,405			1,458,841		13
Black-Scholes assumptions as of at July 8,
2014 (close of IPO)
Remaining term (years)							1			1.8			4.9			4.9
Estimated volatility							70.5	%			68.5	%		82	%		82	%
Risk-free interest rate							0.12	%			0.33	%		1.52	%		1.52	%
Number of warrants remaining							411,060				179,372			620,294			2,076,125
Estimated fair value at July 8, 2014		$	(*	)			1,395				2,539			70,381			235,564			309,879		—
(close of IPO)		$	(*	)			1,395				2,539			70,381			235,564			309,879		—

(*)	This warrant expired unexercised on March 18, 2014
In connection with the closing of our IPO, each of the preferred stock warrants automatically converted into a warrant to purchase share of common stock with substantially the same terms, except the term was extended to five years from the close of the IPO for all of the warrants except the Financing agreement warrants.
In addition to the warrants above, the Company has recorded the estimated value of the warrants related to the 2013 Note discussed in Note 6 that were ultimately issued upon the completion of the IPO. The estimated value of these warrants as of December 31, 2013included in the long-term portion of fair value of warrants. On July 8, 2014 we completed our IPO and pursuant to the 2013 Note’s terms, we issued to the holder of the Note a warrant exercisable for 12,373 shares of our common stock at an exercise price of $10.00 per share. The warrants had an estimated fair value of $106,087 as of December 31, 2013 determined using the Black-Scholes option pricing model, and the following assumptions: 10-year term, 85.17% volatility, and a risk-free interest rate of 2.67%. The estimated fair value as of July 8, 2014 (the close of the IPO) of $104,055 was determined using the Black-Scholes option pricing model, and the following assumptions: 9.4 year remaining term, 91.0% volatility, and a risk-free interest rate of 2.60%. These warrants were classified as liabilities as they were exercisable into redeemable preferred stock until the closing of our IPO on July 8, 2014, at which time they were reclassified as a component of additional paid-in capital.
2014 Notes Warrants
As part of the issuance of the 2014 Notes (see Note 6), the Company issued warrants to the holders of the 2014 Notes with the following terms:
·	Five year exercise period.
·	Exercisable into a newly issued series of preferred stock if an initial public offering or subsequent round of equity financing is not completed prior to January 31, 2015. If an initial public offering occurs prior to January 31, 2015, the warrants will be exercisable into common stock. If an initial public offering does not occur and a subsequent round of financing occurs, then the warrants will be exercisable into the equity securities issued in the subsequent round of financing.
·	The exercise price will be equal to the issuance price of the securities that the warrants are ultimately exercisable into.
·	The number of shares received upon exercise will be equal to the face value of the 2014 Notes ($7,500,000) plus interest accrued divided by the applicable exercise price.
The Company engaged a third-party valuation firm to value the warrants as of the commitment date of the 2014 Notes. Due to the various exercise prices and securities that the warrants are exercisable into, the methodology to value the warrants included a combination of Black-Scholes and Monte Carlo Simulation models that take into consideration probability factors of the various outcomes related to the exercise terms of the warrants. This valuation resulted in an initial valuation of these warrants of $4,454,397.
The placement agent of the 2014 Notes also received warrants as compensation for the placement of the 2014 notes. The warrant coverage received by the placement agent is equal to 10% of the total face value of the 2014 Notes ($750,000) and 10% of the warrant coverage received by the holders of the 2014 Notes ($750,000). The terms of the placement agent warrants are the same as the warrants held by the 2014 Notes holders except for modified warrant coverage and exercise prices on warrants issued related to the face value of the 2014 Notes. The valuation of these warrants was consistent with the above methodology and resulted in an initial valuation of $876,778.
These warrants were classified as liabilities as they were exercisable into redeemable preferred stock until the closing of our IPO on July 8, 2014, at which time they were reclassified as a component of additional paid-in capital.
Pursuant to ASC Topic 480, the estimated fair value of these warrants are reported as liabilities at their estimated fair value at December 31, 2013, and any changes in fair value during the period are reflected in change in value of warrants and put and call options.
(j)	Common Stock
On July 8, 2014, the Company authorized 100,000,000 shares of common stock with a $0.001 par value, of which 5,751,574 shares were issued or outstanding as of December 31, 2014. There are an additional 927,069 shares of common stock issuable upon exercise of outstanding warrants, all of which will be eligible for sale in the public market to the extent permitted by the same restrictions.

Deferred_Revenue

Deferred Revenue	12 Months Ended
Deferred Revenue	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	-8	Deferred Revenue
	Deferred revenue consisted of the following as of:

			Year ended December 31,
			2014			2013
	Celgene		$	10,751,120			14,169,164
	Gilead			32,949			244,711
	Total deferred revenue			10,784,069			14,413,875
	Less: current portion			(3,340,571	)		(3,756,899	)
	Deferred revenue, long-term		$	7,443,498			10,656,976

	(a)	Celgene Agreements
	In May 2009, the Company entered into a Collaboration and Option Agreement with Celgene for the early development of four oncology products and all future oncology drug candidates (which options to future oncology drug candidates were subject to expiration if Celgene did not license one of the initial four named products). Celgene was also a holder of Series C, D and E preferred stock. Under the collaboration agreement, Celgene has the option to obtain an exclusive worldwide license to develop and commercialize the products subject to diligence requirements, an up-front development funding fee, milestone payments and royalties. This agreement was amended in June 2011 to replace one of the four named products with another oncology Tarmogen product. The terms of the amendment did not materially modify the agreement as the financial terms and the length of the agreement remained substantially the same. Celgene’s options with respect to the GI-6200 and GI-3000 oncology drug candidate programs will terminate if Celgene does not exercise its options for such programs after the Company delivers certain reports on predefined clinical trials with respect to such drug programs. In March 2013, Celgene declined to exercise its option to the GI-4000 program and returned all rights and development responsibility to the Company. In July 2013, Celgene exercised its option to license the GI-6300 program. As a result of the election to license the GI-6300 program, Celgene has an option to license all future oncology drug candidates developed by the Company on a product by product basis.
	In July 2013, Celgene exercised its option to license the GI-6300 program, including GI- 6301, in exchange for an upfront payment of $9,000,000. As part of that exercise, the Collaboration and Option Agreement was amended as it related to the GI-6300 program. The agreement, as amended, includes (1) a license granted to Celgene as of the date of the exercise of the option to develop and commercialize the GI-6300 product candidates using all of the Company’s related patents, intellectual property and know-how related to these product candidates that existed at the inception of the Collaboration and Option Agreement or any time during the term, (2) the Company supplying drug product for the Phase 2 clinical trial and (3) the Company’s option to perform Phase 2 clinical trials, subject to Celgene’s right to assume performance of those trials. As part of this exercise, certain milestones were modified and adjustments to the royalty rates on net sales were reduced. The modification to the milestones did not materially impact the deliverables that existed at the time of the modification.
	The Collaboration and Option agreement, as amended including the amendment relating to the GI-6300 program contain the following provisions:
	·	The Company received a $30,000,000 upfront payment to perform research and development and for the option to license products based on the GI-4000, GI-6200, GI-6300 and GI-3000 programs. This payment was made by Celgene in May 2009.
	·	The Company received $1,000,000 in October 2011 and $300,000 in April 2012 from Celgene for additional immunology work for the GI-4000 program.
	·	The Company may receive a total of $85,000,000 in development and regulatory milestones for the GI-6200 and GI-3000 programs; activities for which the Company is not responsible for completing.
	·	If Celgene exercises its option to the GI-6200 or GI-3000 program and these products are commercialized, the Company may also receive up to $60,000,000 in net sales milestones and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which the Company is not responsible for completing.
	·	The Company is eligible to receive a total of $85,000,000 in development and regulatory milestone payments for GI-6301; activities for which the Company is not responsible for completing.
	·	If GI-6301 is commercialized by Celgene, the Company may receive up to $60,000,000 in sales milestone payments for which the Company is not responsible for completing. and tiered royalty rates on net sales ranging from single digits to low double digits
	·	For programs other than GI-6200, GI-3000 and GI-6300, the Company may be eligible to receive up to $101,000,000 in development and regulatory milestone payments for Celgene’s clinical trials, NDA filing and regulatory approvals, up to $60,000,000 in net sales milestone payments for such programs, and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which the Company is not responsible for completing.
	Upon execution of the May 2009 agreement, the Company estimated that its obligations to perform research and development under the agreement would continue through September 30, 2016 and accordingly was recognizing as revenue the upfront fees received of $31,300,000 from the date of receipt through September 30, 2016. The Company reviews the term of performance on a quarterly basis and adjusts the revenue recognition period if there are any changes. As of December 31, 2014 and 2013, the unamortized balance was amortized on a straight line basis through March 31, 2018.
	The Company determined that there were two units of accounting under the July 2013 GI-6300 License Agreement with Celgene: the license to further develop and commercialize GI-6300 and undelivered items related to supplying drug product for the Phase 1 clinical trial and the option to perform the Phase 2 clinical trial (subject to Celgene’s right to assume performance of those trials). The Company determined that the license had standalone value based on the fact that the drug candidate has been developed and is currently in a clinical trial, Celgene possesses the knowledge, technology, skills, experience and background necessary for all further development of the drug through commercialization, the Company is not required to perform any additional development work related to GI-6300 and Celgene has the right to sublicense the product. The Company allocated the $9,000,000 of proceeds to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license based upon a third party valuation and vendor specific objective evidence for the undelivered items. The allocation resulted in $8,766,881 being allocated to the license and the remaining amount of $233,119 allocated to the undelivered items. The Company recognized $8,766,881 in revenue related to the license in the fourth quarter of 2013 upon the delivery of all intellectual property, reports and documentation for the license to Celgene. Revenue related to the undelivered items will be recognized as the services are performed. The current estimated service period for the undelivered items under the GI-6300 License Agreement is through December 2015.
	The Company recognized $3,279,069, $3,307,338 and $3,622,764 in revenue related to research and development services and other services during the years ended December 31, 2014, 2013 and 2012, respectively, and license revenue of $138,975 and $8,766,881 during the years ended December 31, 2014 and 2013, respectively. Costs incurred under these agreements, included in costs of collaboration licenses and services in the Company’s statement of operations and comprehensive income and loss, for the years ended December 31, 2014, 2013 and 2012 were $2,563,409, $2,515,055 and $8,184,806, respectively.
	To date, the Company has not recognized any revenue in connection with milestone payments, other than the license election noted above, or royalties under this agreement.
	(b)	Gilead Agreement
	In October 2011, the Company entered into a License and Collaboration Agreement with Gilead, granting Gilead an exclusive license to all hepatitis B Tarmogen product candidates to be developed and commercialized under the collaboration, which includes a license granted at contract outset to develop and commercialize the HBV Tarmogen product candidate GS-4774 using all of the Company’s related patents, intellectual property and know-how related to these product candidates. Under the terms of the agreement, in November 2011 Gilead made a $10,000,000 initial nonrefundable payment to the Company. The Company conducted preclinical development, filed the Investigational New Drug application (IND) and performed the initial Phase 1a trial in healthy volunteers for the selected HBV Tarmogen. Gilead reimbursed the Company on a periodic basis for the costs and expenses of the Phase 1a clinical trial. Gilead will perform any future clinical development, regulatory, manufacturing and commercialization activities. Gilead activities are subject to commercially reasonable diligence, milestone payments and royalties. Upon satisfaction of certain substantive milestone events for which the Company was partially responsible for completing, the Company received $2,000,000 upon filing an IND for HBV in 2012 and $3,000,000 at the point of commencement of the Phase 1b/2a clinical trial in 2013. The Company is also eligible to receive additional proceeds of up to $130,000,000 in development and regulatory milestones based upon achievement of such milestones by Gilead. If products are commercialized, the Company is eligible to receive tiered royalty rates in the upper single digit to mid-teens and up to $40,000,000 of sales milestone payments based on net sales of the licensed product candidates. The Company is not responsible for the sales efforts.
	The Company determined there was one unit of accounting under the agreement with Gilead. The non-contingent deliverables under the agreement include: the license to all intellectual property and know-how related to hepatitis B Tarmogen products, the services to be performed in preclinical development (including the filing of an IND) and in conducting the Phase 1a clinical trial, participation on the Joint Research and Development Committee (JRC), and the requirement to provide consultation to Gilead after Gilead assumes control of development activities. The Company has estimated the performance period for these deliverables to be from October 2011 through 2020.
	When the agreement was signed, the Company determined that its obligation to supply drug product to Gilead after Gilead assumed control of the development was a contingent deliverable, as the obligation to supply product was contingent on the successful development of the Hepatitis B Tarmogen product candidate and the related approval of the IND among other items. Subsequently, Gilead has assumed control of manufacturing. However, a services agreement between the parties also continues to exist. As a result, the services agreement deliverables and the potential incremental fees to be received by the Company will be accounted for only if and when delivery takes place. The Company has determined that the consideration to be received is an appropriate incremental fee and, therefore there is not a significant incremental discount associated with the selling price of the services agreement.
	The Company determined that the license did not have standalone value at the inception of the agreement. This determination is based on the fact that the license is not sold on a standalone basis, nor could it be resold by Gilead on a standalone basis because the Company has proprietary knowledge, technology, skills, experience and background that no other third party, including Gilead, currently possesses and could not readily obtain at contract inception. Such knowledge, technology, skills, experience and background would be necessary for further development of the Hepatitis B Tarmogen product candidate as required under the agreement.
	The Company is recognizing the initial consideration of $10,000,000 and the amounts it will receive as reimbursement from Gilead of costs to perform the initial Phase 1a trial on a proportional performance basis over the estimated period of performance to complete the preclinical development and Phase 1a trial services, JRC and consultation services, which is estimated to be from October 2011 through 2020. The Company will measure its progress under the proportional performance method based on hours incurred in proportion to total estimated hours. However, the cumulative revenue recognized under this agreement will be limited to the cumulative cash received to date from Gilead. The Company incurred substantially all of the Company hours during the preclinical development and Phase 1a trial period, which ended in February 2014.
	The contractual term of the license is on a product and country basis that begins on the effective date of the contract, October 2011, and runs through the expiration of Gilead’s obligation to pay royalties for such product in such country, or until the agreement is terminated. The JRC term is from the effective date of the agreement and terminates at the end of the Research Term, which is the period of time commencing on the date the agreement was signed and ending upon completion of the final clinical study report for the Gilead Phase 1b/2a trial. The consulting term begins upon the conclusion of the Research Term, and the Company estimates the term would end upon commercialization, currently estimated in 2020.
	The Company recognized $221,392, $4,039,538 and $9,018,842 in license and services revenue under the arrangement during the years ended December 31, 2014, 2013 and 2012, respectively. The Company also recognized milestone payments of $3,000,000 in 2013 and $2,000,000 in 2012. In addition, the Company recognized revenue of $1,539,820 and $3,168,237 during the years ended December 31, 2014 and 2013, respectively, related to manufacturing supply for Phase 2 trials for which Gilead is responsible for performing. Collaboration license and service costs incurred under these agreements, included in costs of collaboration licenses and services in the Company’s statement of operations and comprehensive income and loss, for the years ended December 31, 2014, 2013 and 2012 were $817,103, $3,340,958 and $1,848,234, respectively. Manufacturing services costs incurred under agreements with Gilead, included in costs of manufacturing services in the Company’s statement of operations and comprehensive income and loss, for the years ended December 31, 2014 and 2013 were $1,539,820 and $3,168,237, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	-9	Commitments and Contingencies
	(a)	Contract Commitments
	The Company has an exclusive license with the University of Colorado (CU) that is used in its research and development activities. This agreement requires the Company make certain development milestone payments, make royalty payments based on sales of approved products, if any, and pay a portion of any consideration received by the Company in exchange for granting a sublicense. Under this agreement, the Company is required to pay to CU certain development milestone payments totaling $150,000 per product candidate beginning upon the filing of an IND through the approval from the FDA and royalties on sales of any products and pay a portion of any consideration the Company receives in exchange for granting a sublicense. After the first commercial sale of the licensed products, each milestone payment shall be credited against future royalties, until the full amount of such milestone payment has been credited in full. In 2014, 2013 and 2012, CU was due $5,000, $450,000 and $325,000, respectively, under this agreement.

	The Company has entered into a collaboration agreement with the NIH for the preclinical and clinical development of the Company’s proprietary yeast-based Tarmogens expressing tumor-associated antigens as potential vaccines for the prevention and/or therapy of a range of human cancers. The Company has the right to terminate this agreement with 60 days notice. The agreement requires the Company to make annual payments of up to $300,000 based on the clinical trial stage. The Company made payments of $300,000, $300,000 and $250,000 in years ended December 31, 2014, 2013 and 2012, respectively.
	The Company is a party to two license agreements with the NIH as of December 31, 2014, consisting of the NIH VirusPlus Agreement, dated August 23, 2011 and the NIH CEA Agreement, dated June 12, 2007, collectively referred to as the NIH license agreements. The NIH license agreements grant the Company worldwide, exclusive licenses to make and have made, to use and have used, to sell and have sold, to offer to sell and have offered for sale, and to import and have imported products relating to the use of the Tarmogen immunotherapy platform with certain antigens, other immunotherapy platforms and other intellectual property to treat cancer that are covered by licensed patent rights and to practice and have practiced any licensed processes in the licensed fields of use. These license agreements required the Company to make certain noncreditable and nonrefundable initial royalty payments upon signing of each license agreement, make certain milestone payments upon achievement of specified development and commercial milestones, make royalty payments based on sales of approved products, if any and pay a portion of any consideration received by the Company in exchange for granting a sublicense. The NIH license agreements contain the following provisions:
	·	Under the NIH VirusPlus agreement, the Company is required to make royalty advances totaling $500,000 beginning upon the first filing of an application for marketing approval through the first commercial sale, and royalty payments once it begins selling products developed under the agreement.
	·	Under the NIH CEA agreement, the Company is required to make royalty advances totaling $745,000 beginning upon the filing of an IND through FDA approval, and royalty payments once it begins selling products developed under the agreement.
	In January 2012, and amended in December 2014, the Company signed an exclusive Brachyury license agreement with the NIH and March 2012 an exclusive MUC1 license agreement with the NIH, collectively referred to as the 2012 NIH license agreements. The 2012 NIH license agreements grant the Company worldwide, exclusive licenses to make and have made, to use and have used, to sell and have sold, to offer to sell and have offered for sale, and to import and have imported products relating to the use of the Tarmogen immunotherapy platform with certain antigens, other immunotherapy platforms and other intellectual property to treat cancer that are covered by licensed patent rights and to practice and have practiced any licensed processes in the licensed fields of use. These license agreements require the Company to make certain royalty payments based on sales of approved products, if any, and pay a portion of any consideration the Company receives in exchange for granting a sublicense. In addition, the 2012 NIH license agreements contain the following provisions:
	·	Under the NIH Brachyury Agreement the Company is required to make royalty advances totaling $800,000 beginning upon the successful completion of the first Phase 3 clinical study through the first commercial sale, and royalty payments once it begins selling products developed under the agreement.
	·	Under the NIH MUC1 Agreement the Company is required to make royalty advances totaling $500,000 beginning upon the acceptance of the first filing of an application for marketing approval with the FDA through the first commercial sale, and royalty payments once it begins selling products developed under the agreement.
	(b)	Lease Commitments
	In April 2014, the Company amended the lease agreement for its office and research facility in Louisville, Colorado. The amendment extended the term five years. The amendment includes escalating rent payments throughout the term. The rent expense related to this lease is recorded monthly on a straight-line basis.
	Including the lease amendment, future minimum lease payments under the Company’s noncancelable operating leases are as follows as of December 31, 2014:

	2015		$	595,747
	2016			609,339
	2017			627,702
	2018			646,475
	2019			162,798
			$	2,642,061

	During 2014, 2013 and 2012, the Company incurred rental expense of $598,315, $448,664 and $398,069, respectively.

Benefit_Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Compensation and Employee Benefit Plans [Text Block]	-10	Benefit Plan
	The Company has adopted a 401(k) plan that covers substantially all employees who are at least 21 years of age. The plan is a defined contribution plan to which the employees may contribute up to 60% of their compensation. The Company does not match employee contributions.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	-11	Income Taxes
	The Company has incurred net losses every year, except for 2013, and expects to incur losses in the future. As a result, the Company did not record a federal income tax provision or benefit during 2014 and 2012. In 2013, the Company recorded a current state tax provision of $115,765 which was recorded due to statutory limitations in the use of state net operating loss carryforwards.
	A reconciliation of income taxes at the statutory federal income tax rate to net income taxes included in the accompanying statements of operations is as follows:

			Year Ended December 31,
			2014				2013				2012
	U.S. federal income tax expense at the statutory			(34.0	)	%		34		%		(34.0	)	%
	rate			(34.0	)	%		34		%		(34.0	)	%
	State income taxes, net of federal taxes			(1.4	)			4.1				(7.2	)
	Available research credits			(2.4	)			(9.3	)			—
	Effect of permanent differences			22.2				(5.8	)			(27.2	)
	Change in valuation allowance			15.6				(21.8	)			68.4
	Total			—		%		1.2		%		—		%

	Deferred tax assets and liabilities reflect the net tax effects of net operating loss carryforwards, credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The components of the Company’s deferred tax assets and liabilities are as follows:

			December 31,
			2014				2013
	Accrued benefits		$		93,380			99,494
	Net operating loss carryforwards				44,142,487			40,636,733
	Research credit carryforwards				7,045,830			6,661,348
	Deferred revenue				4,138,236			5,295,697
	Depreciation of property and equipment				1,351,186			1,532,398
	Other				111,250			116,537
	Total deferred tax assets				56,882,369			54,342,207
	Valuation allowance				(56,882,369	)		(54,342,207	)
	Deferred tax assets, net of valuation allowance		$		—			—

	Based upon the level of historical taxable losses and projections of future taxable losses over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences and accordingly has established a full valuation allowance as of December 31, 2014 and 2013. The increase in valuation allowance was $2,540,162 in 2014. In 2013, the valuation allowance decreased by $2,085,277.
	Future realization depends on the future earnings of the Company, if any, the timing and amount of which are uncertain as of December 31, 2014. In the future, should management conclude that it is more likely than not that the deferred tax assets are, in fact, at least in part, realizable, the valuation allowance would be reduced to the extent of such realization and recognized as a deferred income tax benefit in the Company’s Statements of Operations and Comprehensive Loss.
	As of December 31, 2014, the Company had available total federal and state net operating loss carryforwards of approximately $116,200,000, which expire in the years 2022 through 2034, and federal research credit carryforwards of $7,000,000, which expire in the years 2022 through 2034. The utilization of the net operating loss carryforwards and research credits may be limited due to the provisions of Sections 382 and 383 of the Internal Revenue Code if there are significant changes in ownership. Due to the nature of changes of ownership during 2003 and 2007, there will be limitations in the Company’s ability to utilize existing net operating loss carryforwards in future periods. The Company has not completed its analysis of any potential Section 382 ownership changes for the year ended December 31, 2014, but the Company anticipates that such an ownership change may have occurred in July 2014 upon the closing of its IPO which will limit its ability to utilize its federal net operating loss carryforwards (and certain other tax attributes) that accrued prior to the IPO.
	The Company has adopted the authoritative guidance under U.S. GAAP related to the accounting for uncertainty in income taxes, including derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company has evaluated tax positions taken or expected to be taken in the course of preparing the financial statements to determine if the tax positions are “more likely than not” of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more likely than not” threshold would be recorded as a tax benefit or expense in the current year. The Company has concluded that there was no impact related to uncertain tax positions on the results of its operations for the years ended December 31, 2014, 2013 and 2012. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as income tax expense. As of December 31, 2014 and 2013, the Company has no accrued interest or penalties related to uncertain tax positions. The Company’s conclusions regarding tax positions will be subject to review and may be adjusted at a later date based on factors including, but not limited to, ongoing analyses of tax laws, regulations, and interpretations thereof. The United States is the major tax jurisdiction for the Company, and the earliest tax year subject to examination is 2002, which includes the earliest year for which net operating loss carryforwards are available.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Financial Statements	(a)	Use of Estimates in the Preparation of Financial Statements
Use of Estimates in the Preparation of Financial Statements	The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management of the Company to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated accrued expenses, the impairment of long-lived assets, the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock.
Initial Public Offering	(b)	Initial Public Offering
Initial Public Offering	The Company completed an initial public offering (IPO) on July 8, 2014. In the offering, we sold 1,725,000 shares of our common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses. Upon completion of the offering, all of our then outstanding preferred stock converted into 2,757,825 shares of our common stock in accordance with the terms of the preferred stock, all of our outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the 2013 Note and the 2014 Notes, described in note 6, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the 2013 Note upon such conversion and the warrants issued to the holders of the 2014 Notes become exercisable for 12,373 and 750,000 shares of common stock, respectively.
Reverse Stock Split	(c)	Reverse Stock Split
Reverse Stock Split	On April 25, 2014, the Company affected a 1-for-4.3 reverse stock split of the Company’s common stock after approval by the Company’s stockholders. In connection with the reverse stock split, the Company filed a Certificate of Amendment of its Restated Certificate of Incorporation with the Secretary of State of Delaware on April 25, 2014 affecting the reverse stock split. This reverse stock split has been reflected retroactively for all periods presented in the financial statements.
Cash and Cash Equivalents	(d)	Cash and Cash Equivalents
Cash and Cash Equivalents	The Company considers all highly liquid instruments purchased with original maturity dates of 90 days or less to be cash equivalents. The Company places its temporary cash investments on deposit with financial institutions it believes to be of high quality. Cash equivalents have maturities of 90 days or less, and their carrying amounts approximate fair value.
Concentrations of Credit Risk	(e)	Concentrations of Credit Risk
Concentrations of Credit Risk	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio, and making investments with maturities that maintain safety and liquidity. At December 31, 2014, 2013 and 2012, the Company’s cash equivalents were with money market funds that invest in securities issued by the U.S. Treasury.
Property, Plant and Equipment	(f)	Property and Equipment
	Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and major additions, replacements, and improvements are capitalized. Leasehold improvements are amortized over the shorter of the related lease term or the estimated useful life.


	Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows:



	Furniture and fixtures		7 years
	Leasehold improvements		Lesser of useful life or life of the lease
	Laboratory machinery and equipment		5 years
	Computer equipment		3 years
	The cost of assets sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected in the statements of operations and comprehensive income and loss in the period in which such sale or disposition occurs. Depreciation and amortization expense for the years ended December 31, 2014, 2013 and 2012 was $295,165, $771,280 and $925,473, respectively.
Impairment of Long - Lived Assets	(g)	Impairment of Long-Lived Assets
Impairment of Long - Lived Assets	The Company reviews its long-lived assets, consisting of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from future undiscounted cash flows. Impairment losses are recorded for the difference between the carrying value and the estimated fair value of the long-lived assets. The Company has not yet generated consistent positive cash flows on an annual basis, and such positive cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired.
Restricted Cash	(h)	Restricted Cash
Restricted Cash	As of December 31, 2014 and 2013, restricted cash, classified as long-term assets in the accompanying balance sheets consisted of a security deposit for the lease agreement for the corporate headquarters building.
Accrued bLiabilities	(i)	Accrued Liabilities
	The Company makes estimates of its accrued expenses by identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of the Company’s service providers invoice it monthly in arrears for services performed. Examples of estimated accrued expenses include:
	·	fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials;
	·	fees owed to investigative sites in connection with clinical trials;
	·	fees owed to contract manufacturers in connection with the production of clinical trial materials;
	·	fees owed for professional services;
	·	property taxes; and
	·	unpaid salaries, wages, and benefits.
	Accrued liabilities consisted of the following as of:

			Year ended December 31,
			2014			2013
	Accrued compensation			578,091		$	278,108
	Accrued clinical trial holdbacks			32,385			126,455
	Income taxes		—				115,765
	Other			648,856			400,634
	Total Accrued Liabilities			1,259,332		$	920,962

	As of December 31, 2014 and 2013, accrued liabilities included $32,385 and $126,455 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by the Company.
Deferred Revenue	(j)	Deferred Revenue
Deferred Revenue	The Company records amounts received but not earned under its collaboration agreements as deferred revenue, which are then classified as either current or long-term in the accompanying balance sheets based on the period during which they are expected to be recognized as revenue.
Stock Based Compensation	(k)	Stock-Based Compensation
	The Company accounts for stock compensation pursuant to ASC Topic 718, Compensation-Stock Compensation. The Company applies the straight-line attribution method and, accordingly, amortizes the fair value of each option over the requisite service period through the last separately vesting portion of the award. Employee stock options granted by the Company are generally structured to qualify as “incentive stock options” (ISOs). Under current tax regulations, the Company does not receive a tax deduction for the issuance, exercise, or disposition of ISOs if the employee meets certain holding requirements. If the employee does not meet the holding requirements, a disqualifying disposition occurs, at which time the Company may receive a tax deduction. The Company does not record tax benefits related to ISOs unless and until a disqualifying disposition occurs.
	The Company accounts for stock options issued to nonemployees in accordance with the provisions of ASC Topic 718 and ASC Subtopic 505-50, Equity-Based Payments to Nonemployees , which requires valuing the stock options using a Black-Scholes option pricing model and remeasuring such stock options to their current fair value until the performance date has been reached.
Income Taxes	(l)	Income Taxes
	The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes, which requires the use of the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for operating loss and tax credit carryforwards. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.
	The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. As of December 31, 2014 and 2013, the Company has no unrecognized uncertain tax positions.
Fair Value of Financial Instruments	(m)	Fair Value of Financial Instruments
	The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accrued liabilities and accounts payable, approximate fair value due to their short-term maturities. The carrying amount of the convertible note payable approximated its fair value as its terms were comparable to what would be included in similar debt instruments.
	The Company accounted for its preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity, and classified warrants for redeemable preferred stock as liabilities. The warrants were reported as short-term or long-term liabilities, depending on their remaining term, at their estimated fair value at December 31, 2013, and any changes in fair value are reflected in changes in value of warrants. The preferred stock warrant liability was reclassified to additional paid-in capital upon the closing of our IPO in July 2014.
	The fair value of all the outstanding warrants at July 8, 2014 (the close of our IPO) and December 31, 2013 was $7,118,054 and $1,564,941, respectively (see note 7).
Segment Information	(n)	Segment Information
Segment Information	The Company operates in one segment, which is the business of developing and commercializing various biopharmaceutical products.
Research and Development Expenses	(o)	Research and Development Expenses
	During 2014, 2013 and 2012, the Company incurred $7,213,416, $10,884,628 and $11,734,551, respectively, in expenses relating to research and development. Research and development costs are expensed as incurred and include costs of collaboration license and services, cost of manufacturing services and research and development for proprietary programs. These costs consist primarily of salaries, supplies, and contract services relating to the development of new products and technologies.
	The Company contracts with third parties to perform a range of clinical trial activities in the ongoing development of its product candidates. The terms of these agreements vary and may result in uneven payments. Payments under these contracts depend on factors such as the progress toward achievement of certain defined milestones, the successful enrollment of patients, and other events.
Revenue Recognition	(p)	Revenue Recognition
	In 2014, 2013 and 2012, the Company’s revenue was in the form of upfront fees derived from the discovery, development and commercialization of multiple product candidates based on targeted molecular immunotherapy for the treatment of cancer and infectious diseases and fees for manufacturing services for the Company’s collaborators. The Company’s agreements with its collaborators include fees based on a nonrefundable upfront fee, nonrefundable milestone payments that are triggered upon achievement of specific development or regulatory goals, and future royalties on sales of products that result from the collaboration (see note 8(a) and 8(b)) and fees for manufacturing services.
	The Company recognizes revenue in accordance with ASC Topic 605 Revenue Recognition (ASC 605). ASC 605 establishes four criteria, each of which must be met, in order to recognize revenue related to the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable, and (d) collectability is reasonably assured.
	The Company evaluates the deliverables under our multiple-element arrangements to determine if they meet the separation criteria in ASC 605-25 and have stand-alone value. The Company allocates revenue to each identified deliverable based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, otherwise known as the relative selling price method. The allocated consideration for each deliverable is then recognized over the related obligation period for that deliverable. The Company treats deliverables in an arrangement that do not meet the separation criteria as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.
	The Company recognizes revenue from nonrefundable upfront payments over the estimated term of performance under the agreements. Since the term is not specifically identifiable in the agreements, management has estimated the performance terms based on the likelihood and forecasted achievement of development commitments, and other significant commitments of the Company. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying balance sheets.
	Management evaluates the likely performance period under its collaboration agreements on a periodic basis. If there are changes to the estimated performance periods as a result of the outcome of certain events, the period over which the nonrefundable upfront payments are recognized will be adjusted prospectively. The events that will impact the estimation of the performance period include, among others, the success of the drug candidate programs and the likelihood of the collaborator exercising their options under the collaboration agreement.
	The Company’s collaboration agreements provide for milestone payments and royalties on future sales. In accordance with the milestone method, each substantive milestone payment is recognized as revenue when the specific milestone is achieved and royalties are recorded when earned.
	Revenue recognition related to upfront payments and to milestone payments could be accelerated in the event of early termination of drug programs or, alternatively, decelerated if programs are extended. As such, while changes to such estimates have no impact on its reported cash flows, the Company’s reported revenue is significantly influenced by its estimates of the period over which its obligations are expected to be performed.
	The Company categorizes its revenues into collaboration license and services, milestones and manufacturing services, substantially all of which come from its collaboration partners.
	In 2013, the Company received a $4,000,000 Research Project Grant by the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institute of Health, or NIH, to support the development of Tarmogen immunotherapy product candidates to treat and prevent tuberculosis infection. This work for this grant will be performed and reimbursed over four years. The Company recognizes revenue from this grant as work is performed.
Net Loss Per Share	(q)	Net Loss per Share
	Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.
	The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders:

			Years ended December 31,
			2014			2013			2012
	Net loss per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common			(23,434,827	)		(3,408,442	)		(14,118,995	)
	stockholders			(23,434,827	)		(3,408,442	)		(14,118,995	)
	Denominator:
	Weighted-average common shares used in computing			2,914,690			92,522			89,377
	net loss per share of common stock - basic and diluted			2,914,690			92,522			89,377
	Net loss per share of common stock attributable to			(8.04	)		(36.84	)		(157.97	)
	GlobeImmune, Inc. stockholders - basic and diluted			(8.04	)		(36.84	)		(157.97	)


	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive:

			Years ended December 31,
			2014			2013			2012

	Weighted-average convertible preferred stock upon			1,428,024			2,757,825			2,757,113
	conversion to common stock (as converted basis) *			1,428,024			2,757,825			2,757,113

	Weighted-average warrants to purchase convertible			411,303			107,057			108,986
	preferred stock as converted basis) *			411,303			107,057			108,986

	Outstanding stock options and warrants to purchase			219,180			229,494			376,880
	common stock at period-end)			219,180			229,494			376,880

	Weighted-average convertible promissory note upon			509,947			6,921			—
	conversion to common stock (as converted basis)			509,947			6,921			—
	Total			2,568,454			3,101,297			3,242,979



	*	The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.
Recently Issued Accounting Standards	(r)	Recently Issued Accounting Standards
	On May 28, 2014, the FASB issued guidance that requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. The new standard is effective for the Company on September 1, 2017, and early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that this new guidance will have on its consolidated financial statements and related disclosures. The Company has not selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and provide related disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January 1, 2017 and is not expected to have a material impact on the Company’s Consolidated Financial Statements. As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, the Company has elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. This election is irrevocable.
Fair Value Measurements	(s)	Fair Value Measurements
	In general, asset and liability fair values are determined using the following categories:
	Level 1– inputs utilize quoted prices in active markets for identical assets or liabilities.
	Level 2– inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
	Level 3– inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own assumptions about the assumptions that a market participant would use.
	The Company’s financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2014 and 2013 approximates fair value based on quoted prices in active markets, or Level 1 inputs. The carrying amount of outstanding warrants and put options as of December 31, 2013 approximates fair value based on unobservable inputs, or Level 3 inputs, using assumptions made by the Company, including pricing, volatility, and expected term. There were no transfers between levels for the years ended December 31, 2014, 2013 and 2012.
	Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2014 and 2013:

	Description		December 31,			Quoted			Significant			December 31,		Quoted		Significant
			2014			prices in			unobservable			2013		prices in		unobservable
						active			inputs					active		inputs
						markets for			(Level 3)					markets for		(Level 3)
						identical								identical
						assets								assets
						(Level 1)								(Level 1)
	Assets measured at fair value:
	Money market investments (included in cash			20,173			20,173			—			20,672		20,672		—
	and cash equivalents)			20,173			20,173			—			20,672		20,672		—
	Liabilities measured at fair value:
	Warrants (included in fair value of warrants)			—			—			—			1,564,941		—		1,564,941
	Put and call options (included in fair value of			—			—			—			101,222		—		101,222
	put and call options and other long-term
	liabilities)

	A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:

			Warrants			Put and call options
	Balance of liability at December 31, 2011			(5,304,530	)	—
	Transfer of fair value of warrants to preferred stock			51,629
	upon exercise			51,629
	Income included in net loss:
	Income due to change in fair value			1,951,490		—

	Balance of liability at December 31, 2012			(3,301,411	)	—
	Issuance of warrants in connection with convertible			(106,087	)	—
	promissory notes			(106,087	)	—
	Issuance of put options in connection with convertible		—				(101,222	)
	promissory notes		—				(101,222	)
	Income included in net income:
	Income due to change in fair value			1,842,557		—

	Balance of liability at December 31, 2013		$	(1,564,941	)		(101,222	)
	Issuance of warrants in connection with convertible			(5,331,175	)	—
	promissory notes			(5,331,175	)	—
	Issuance of put and call options in connection with		—				(1,667,136	)
	convertible promissory notes		—				(1,667,136	)
	Transfer to additional paid-in capital upon completion of			7,118,054			3,449,866
	initial public offering			7,118,054			3,449,866
	Loss included in net loss:
	Loss due to change in fair value			(221,938	)		(1,681,508	)
	Balance of liability at December 31, 2014		$	—			—

	Gains (losses) included in net income and loss for the years ended December 31, 2014, 2013 and 2012 are reported in change in value of warrants.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Property and Equipment, Schedule of Useful Lives

	Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows:



	Furniture and fixtures		7 years
	Leasehold improvements		Lesser of useful life or life of the lease
	Laboratory machinery and equipment		5 years
	Computer equipment		3 years

Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of:

			Year ended December 31,
			2014			2013
	Accrued compensation			578,091		$	278,108
	Accrued clinical trial holdbacks			32,385			126,455
	Income taxes		—				115,765
	Other			648,856			400,634
	Total Accrued Liabilities			1,259,332		$	920,962

Schedule of Net Loss Per Share, Basic and Diluted	The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders:

			Years ended December 31,
			2014			2013			2012
	Net loss per share:
	Numerator:
	Net loss attributable to GlobeImmune, Inc. common			(23,434,827	)		(3,408,442	)		(14,118,995	)
	stockholders			(23,434,827	)		(3,408,442	)		(14,118,995	)
	Denominator:
	Weighted-average common shares used in computing			2,914,690			92,522			89,377
	net loss per share of common stock - basic and diluted			2,914,690			92,522			89,377
	Net loss per share of common stock attributable to			(8.04	)		(36.84	)		(157.97	)
	GlobeImmune, Inc. stockholders - basic and diluted			(8.04	)		(36.84	)		(157.97	)

Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive:

			Years ended December 31,
			2014			2013			2012

	Weighted-average convertible preferred stock upon			1,428,024			2,757,825			2,757,113
	conversion to common stock (as converted basis) *			1,428,024			2,757,825			2,757,113

	Weighted-average warrants to purchase convertible			411,303			107,057			108,986
	preferred stock as converted basis) *			411,303			107,057			108,986

	Outstanding stock options and warrants to purchase			219,180			229,494			376,880
	common stock at period-end)			219,180			229,494			376,880

	Weighted-average convertible promissory note upon			509,947			6,921			—
	conversion to common stock (as converted basis)			509,947			6,921			—
	Total			2,568,454			3,101,297			3,242,979



	*	The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.
Fair Value Measurements, Recurring and Nonrecurring	Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2014 and 2013:

	Description		December 31,			Quoted			Significant			December 31,		Quoted		Significant
			2014			prices in			unobservable			2013		prices in		unobservable
						active			inputs					active		inputs
						markets for			(Level 3)					markets for		(Level 3)
						identical								identical
						assets								assets
						(Level 1)								(Level 1)
	Assets measured at fair value:
	Money market investments (included in cash			20,173			20,173			—			20,672		20,672		—
	and cash equivalents)			20,173			20,173			—			20,672		20,672		—
	Liabilities measured at fair value:
	Warrants (included in fair value of warrants)			—			—			—			1,564,941		—		1,564,941
	Put and call options (included in fair value of			—			—			—			101,222		—		101,222
	put and call options and other long-term
	liabilities)

Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs	A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows:

			Warrants			Put and call options
	Balance of liability at December 31, 2011			(5,304,530	)	—
	Transfer of fair value of warrants to preferred stock			51,629
	upon exercise			51,629
	Income included in net loss:
	Income due to change in fair value			1,951,490		—

	Balance of liability at December 31, 2012			(3,301,411	)	—
	Issuance of warrants in connection with convertible			(106,087	)	—
	promissory notes			(106,087	)	—
	Issuance of put options in connection with convertible		—				(101,222	)
	promissory notes		—				(101,222	)
	Income included in net income:
	Income due to change in fair value			1,842,557		—

	Balance of liability at December 31, 2013		$	(1,564,941	)		(101,222	)
	Issuance of warrants in connection with convertible			(5,331,175	)	—
	promissory notes			(5,331,175	)	—
	Issuance of put and call options in connection with		—				(1,667,136	)
	convertible promissory notes		—				(1,667,136	)
	Transfer to additional paid-in capital upon completion of			7,118,054			3,449,866
	initial public offering			7,118,054			3,449,866
	Loss included in net loss:
	Loss due to change in fair value			(221,938	)		(1,681,508	)
	Balance of liability at December 31, 2014		$	—			—

Cash_and_Cash_Equivalents_Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
Cash and Cash Equivalents (Tables)	Dec. 31, 2014
Cash And Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	The following is a summary of cash and cash equivalents and their fair values at:

		Amortized		Unrealized		Unrealized		Fair market
		cost		gains		losses		value
	31-Dec-13
	Cash	$	5,903,569	$	—	$	—	$	5,903,569
	Money market funds		20,672		—		—		20,672
	Total at December 31, 2013	$	5,924,241	$	—	$	—	$	5,924,241
	31-Dec-14
	Cash	$	16,792,286	$	—	$	—	$	16,792,286
	Money market funds		20,173		—		—		20,173
	Total at December 31, 2014	$	16,812,459	$	—	$	—	$	16,812,459

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property Plant And Equipment [Abstract]
Summary of Components of Property and Equipment	Property and equipment consist of the following at:

		Year ended December 31,
		2014			2013
	Furniture and fixtures		212,471			212,471
	Leasehold improvements		7,617,934			7,563,511
	Laboratory equipment		3,819,740			3,726,953
	Computer and office equipment		617,264			595,872
			12,267,409			12,098,807
	Less accumulated depreciation		(11,811,641	)		(11,606,005	)
			455,768			492,802

Redeemable_Convertible_Preferr1

Redeemable, Convertible Preferred Stock and Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2014
Series B Preferred Stock for Cash and Convertible Promissory Notes Payable	During 2005, the Company closed on several issuances of Series B preferred stock for cash and convertible promissory notes payable at $1.338 per share as follows:

						Amount			Shares
	Initial closing		Jun-05			25,050,000			18,721,973
	Second closing		Jul-05			3,500,001			2,615,845
	Third closing		August 2005			4,750,000			3,550,073
	Fourth closing		September 2005			1,000,000			747,384
	Fifth closing		Sep-05			2,000,000			1,494,768
	Sixth closing		Oct-05			1,000,001			747,385
	Final closing		Dec-05			1,100,001			822,123
						38,400,003			28,699,551

Summary of Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants	The following table summarizes common stock option and warrant activities for common stock options and warrants issued to employees, directors, and consultants:

										Weighted
							Weighted			average
			Number of				average			remaining
			common stock				exercise			contractual
			options				price			term (years)
	Outstanding at December 31, 2011			362,274				7.08
	Granted			27,105				18.24
	Exercised			(4,566	)			4.73
	Canceled			(7,933	)			9.15
	Outstanding at December 31, 2012			376,880				7.87
	Exercised			(382	)			4.73
	Canceled			(147,004	)			7.82
	Outstanding at December 31, 2013			229,494				7.9
	Granted			7,279				15.1
	Exercised			(8,009	)			4.73
	Canceled			(9,584	)			5.86
	Outstanding at December 31, 2014			219,180				8.35			3.8
	Exercisable at December 31, 2014			207,958				7.92			3.6

Exercisable and Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants by Exercise Prices	The following table summarizes information about stock options issued to employees, directors, and consultants that is outstanding at December 31, 2014:

			Common stock options							Common stock options
			outstanding							exercisable
							Weighted
							average						Weighted
							remaining						average
			Number				contractual			Number			exercise
	Exercise price		outstanding				life (years)			exercisable			price
	$ 4.73			56,175				1.34			56,175		$	4.73
	5.04			4,820				2.34			4,820			5.04
	5.98			67,575				3.17			67,575			5.98
	6.93			14,882				4.25			14,882			6.93
	8.52			6,971				4.75			6,971			8.52
	10.07			2,814				6.21			2,814			10.07
	12.56			41,464				5.61			41,464			12.56
	15.10			7,279				9.2			—			15.1
	18.24			17,200				7.24			13,257			18.24
				219,180							207,958

Summary of Preferred Stock Warrants Outstanding, Fair Value of Warrants and Assumptions Used to Estimate Fair Value	The Company had the following preferred stock warrants that vested upon issuance outstanding as of December 31, 2013 and July 8, 2014 (the close of the IPO). Also included below are the Black-Scholes assumptions used to estimate the fair value of the warrants:

																Issuance of
			2004				Convertible			2006			Convertible			Series D			Total		Total
			Financing				promissory			Financing			promissory			preferred			Long-		Short-
	Warrants issued in connection with		agreement				notes			agreement			notes			stock			term		term
	Issue date		March 2004				June 2005			April 2006			May 2009			May 2009
	Redeemable, convertible preferred stock		Series A				Series B			Series B			Series C			Series C
	underlying the warrant		Series A				Series B			Series B			Series C			Series C
	Number of warrants			22,000				411,060			179,372			622,826			2,076,125
	Exercise price		$	1.25			1.338			1.338			1.445			1.445
	Black-Scholes assumptions as of December 31,
	2012
	Remaining term (years)		1.2				2.5			3.3			6.4			6.4
	Estimated volatility			83	%			86.5	%		85.5	%		92	%		92	%
	Risk-free interest rate			0.16	%			0.31	%		0.35	%		0.92	%		0.92	%
	Number of warrants remaining			22,000				411,060			179,372			620,294			2,076,125
	Estimated fair value at December 31, 2012		$	2,837				100,270			52,680			723,631			2,421,993			3,301,411		—
	Black-Scholes assumptions as of December 31,
	2013
	Remaining term (years)		0.2				1.5			2.3			5.4			5.4
	Estimated volatility			61	%			66.5	%		84.5	%		97	%		97	%
	Risk-free interest rate			0.07	%			0.24	%		0.52	%		1.58	%		1.58	%
	Number of warrants remaining			22,000				411,060			179,372			620,294			2,076,125
	Estimated fair value at December 31, 2013		$	13				28,098			32,735			321,603			1,076,405			1,458,841		13
	Black-Scholes assumptions as of at July 8,
	2014 (close of IPO)
	Remaining term (years)							1		1.8			4.9			4.9
	Estimated volatility							70.5	%		68.5	%		82	%		82	%
	Risk-free interest rate							0.12	%		0.33	%		1.52	%		1.52	%
	Number of warrants remaining							411,060			179,372			620,294			2,076,125
	Estimated fair value at July 8, 2014		$	(*	)			1,395			2,539			70,381			235,564			309,879		—
	(close of IPO)		$	(*	)			1,395			2,539			70,381			235,564			309,879		—

	(*)	This warrant expired unexercised on March 18, 2014
Employees
Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees and Non-employees	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for employee grants and used the following assumptions to obtain the weighted average grant date fair values:

			Year Ended December 31,
			2014				2013 (a)			2012
	Risk-free interest rate			1.82%				—			1.30%
	Expected life (in years)			6				—		5.8 - 6.0
	Expected volatility			95.70%				—		90.9% - 91.2%

		(a)There were no stock options granted in 2013.
Non Employees
Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees and Non-employees	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for nonemployee grants and used the following assumptions to estimate fair value each respective year:

			Year Ended December 31,
			2014		2013		2012
	Risk-free interest rate		2.8% -3.0%		1.8% -2.7%		1.4% -2.2%
	Expected life (in years)		10		10		10
	Expected volatility		85.2% -85.4%		82.6% -85.1%		83.3% -85.2%

Deferred_Revenue_Tables

Deferred Revenue (Tables)	12 Months Ended
Deferred Revenue (Tables)	Dec. 31, 2014
Deferred Revenue Disclosure [Abstract]
Components of Deferred Revenue	Deferred revenue consisted of the following as of:

		Year ended December 31,
		2014			2013
	Celgene	$	10,751,120			14,169,164
	Gilead		32,949			244,711
	Total deferred revenue		10,784,069			14,413,875
	Less: current portion		(3,340,571	)		(3,756,899	)
	Deferred revenue, long-term	$	7,443,498			10,656,976

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Including the lease amendment, future minimum lease payments under the Company’s noncancelable operating leases are as follows as of December 31, 2014:

	2015	$	595,747
	2016		609,339
	2017		627,702
	2018		646,475
	2019		162,798
		$	2,642,061

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of income taxes at the statutory federal income tax rate to net income taxes included in the accompanying statements of operations is as follows:

		Year Ended December 31,
		2014				2013				2012
	U.S. federal income tax expense at the statutory		(34.0	)	%		34		%		(34.0	)	%
	rate		(34.0	)	%		34		%		(34.0	)	%
	State income taxes, net of federal taxes		(1.4	)			4.1				(7.2	)
	Available research credits		(2.4	)			(9.3	)			—
	Effect of permanent differences		22.2				(5.8	)			(27.2	)
	Change in valuation allowance		15.6				(21.8	)			68.4
	Total		—		%		1.2		%		—		%

Schedule of Deferred Tax Assets and Liabilities	The components of the Company’s deferred tax assets and liabilities are as follows:

		December 31,
		2014				2013
	Accrued benefits	$		93,380			99,494
	Net operating loss carryforwards			44,142,487			40,636,733
	Research credit carryforwards			7,045,830			6,661,348
	Deferred revenue			4,138,236			5,295,697
	Depreciation of property and equipment			1,351,186			1,532,398
	Other			111,250			116,537
	Total deferred tax assets			56,882,369			54,342,207
	Valuation allowance			(56,882,369	)		(54,342,207	)
	Deferred tax assets, net of valuation allowance	$		—			—

Liquidity_Risks_Additional_Inf

Liquidity Risks - Additional Information (Details) (USD $)	12 Months Ended
Liquidity Risks - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Risks And Uncertainties [Abstract]
Accumulated deficit	($222,704,740)	($199,321,927)
Net income (loss)	-16,260,926	9,476,699	-2,014,744
Net cash provided by (used in) operating activities	($10,051,096)	$3,931,727	($13,068,040)

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	0 Months Ended	12 Months Ended			0 Months Ended
	Apr. 25, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 08, 2014
	Apr. 25, 2014	Segment	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Jul. 08, 2014
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of common stock		$14,619,859
Reverse Stock Split, description	On April 25, 2014, the Company affected a 1-for-4.3 reverse stock split of the Companybs common stock after approval by the Companybs stockholders.
Liquid instruments maturity date		90 days or less
Cash equivalents maturity date		90 days or less
Depreciation and amortization		295,165	771,280	925,473
Accrued clinical trial holdbacks		32,385	126,455		126,455
Percentage of holdbacks on payments due to entities		5.00%
Unrecognized uncertain tax positions		0	0		0
Warrants outstanding, fair value			1,564,941		1,564,941	7,118,054
Number of operating segment		1
Research and development expense		7,213,416	10,884,628	11,734,551
National Institute of Allergy and Infectious Diseases
Summary Of Significant Accounting Policies [Line Items]
Receipt of research project grant					4,000,000
Performance and reimbursement period					4 years
2013 Notes
Summary Of Significant Accounting Policies [Line Items]
Conversion of preferred stock warrants into common stock						51,556
Common Stock to be issued up on exercise of warrants						12,373
2014 Convertible Notes
Summary Of Significant Accounting Policies [Line Items]
Conversion of preferred stock warrants into common stock						1,116,372
Common Stock to be issued up on exercise of warrants						750,000
IPO
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued						1,725,000
Common stock, par value						$10
Proceeds from issuance of common stock						$17,250,000
Conversion of preferred stock to common stock						2,757,825

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2014
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	7 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives description	Lesser of useful life or life of the lease
Laboratory Machinery and Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	5 years
Computer Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	3 years

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Accrued Liabilities And Other Liabilities [Abstract]
Accrued compensation	$578,091	$278,108
Accrued clinical trial holdbacks	32,385	126,455
Income taxes		115,765
Other	648,856	400,634
Total Accrued Liabilities	$1,259,332	$920,962

Summary_of_Significant_Account6

Summary of Significant Accounting Policies - Schedule of Net Loss Per Share, Basic and Diluted (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss attributable to GlobeImmune, Inc. common stockholders	($23,434,827)	($3,408,442)	($14,118,995)
Denominator:
Weighted-average common shares used in computing net loss per share of common stock - basic and diluted	2,914,690	92,522	89,377
Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted	($8.04)	($36.84)	($157.97)

Summary_of_Significant_Account7

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013		Dec. 31, 2012
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	2,568,454		3,101,297		3,242,979
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	1,428,024	[1]	2,757,825	[1]	2,757,113	[1]
Warrants to Purchase Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	411,303	[1]	107,057	[1]	108,986	[1]
Options and Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	219,180		229,494		376,880
Convertible Promissory Note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	509,947		6,921

[1]	The convertible preferred stock and convertible preferred stock warrants were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.

Summary_of_Significant_Account8

Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) (USD $)	Jul. 08, 2014	Dec. 31, 2013	Dec. 31, 2014
Liabilities measured at fair value:
Warrants outstanding, fair value	$7,118,054	$1,564,941
Fair Value, Measurements, Recurring
Assets measured at fair value:
Money market investments (included in cash and cash equivalents)		20,672	20,173
Liabilities measured at fair value:
Warrants (included in fair value of warrants)		1,564,941
Warrants outstanding, fair value		101,222
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets measured at fair value:
Money market investments (included in cash and cash equivalents)		20,672	20,173
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Liabilities measured at fair value:
Warrants (included in fair value of warrants)		1,564,941
Warrants outstanding, fair value		$101,222

Summary_of_Significant_Account9

Summary of Significant Accounting Policies - Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Put Options
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance of liability	($101,222)
Issuance of warrants in connection with convertible promissory notes	-1,667,136	-101,222
Transfer to additional paid-in capital upon completion of initial public offering	3,449,866
Income (loss) due to change in fair value	-1,681,508
Ending Balance of liability		-101,222
Warrant
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance of liability	-1,564,941	-3,301,411	-5,304,530
Transfer of fair value of warrants to preferred stock upon exercise			51,629
Issuance of warrants in connection with convertible promissory notes	-5,331,175	-106,087
Transfer to additional paid-in capital upon completion of initial public offering	7,118,054
Income (loss) due to change in fair value	-221,938	1,842,557	1,951,490
Ending Balance of liability		($1,564,941)	($3,301,411)

Cash_and_Cash_Equivalents_Sche

Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Cash And Cash Equivalents [Line Items]
Amortized cost	$16,812,459	$5,924,241
Fair market value	16,812,459	5,924,241
Cash
Cash And Cash Equivalents [Line Items]
Amortized cost	16,792,286	5,903,569
Fair market value	16,792,286	5,903,569
Money market funds
Cash And Cash Equivalents [Line Items]
Amortized cost	20,173	20,672
Fair market value	$20,173	$20,672

Property_and_Equipment_Summary

Property and Equipment - Summary of Components of Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property Plant And Equipment [Line Items]
Property and equipment, gross	$12,267,409	$12,098,807
Less accumulated depreciation	-11,811,641	-11,606,005
Property and equipment, net	455,768	492,802
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	212,471	212,471
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,617,934	7,563,511
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	3,819,740	3,726,953
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$617,264	$595,872

Convertible_Notes_Additional_I

Convertible Notes - Additional Information (Details) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended	2 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jul. 08, 2014	Nov. 30, 2013	Feb. 28, 2014
Debt Instrument [Line Items]
Convertible promissory note		$197,955
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs	3,562,946	9,268
Loss on extinguishment of convertible notes	-4,687,649
Fair value of warrants issued for debt issuance costs	876,778
2013 Notes
Debt Instrument [Line Items]
Convertible promissory note				391,730
Convertible promissory note , interest rate				8.00%
Debt instrument, expiry period				3 years
Price per share of common stock as a percentage IPO price				80.00%
Warrant coverage percentage of notes				30.00%
Fair value of warrants attached to convertible promissory note				106,087
Fair value put option embedded in convertible promissory note				101,222
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs				207,309
Amortization of debt discount	35,749	9,268
Unamortized balance of debt discount		198,041
Conversion of preferred stock warrants into common stock			51,556
Conversion price per share			$8
Debt instrument, convertible, carrying amount of debt			352,986
Accrued interest			20,718
Loss on extinguishment of convertible notes			162,574
Common Stock to be issued up on exercise of warrants			12,373
Class of warrant or right, exercise price of warrants or rights			$10
2013 Notes \| Warrants to Purchase Convertible Preferred Stock
Debt Instrument [Line Items]
Debt instrument, expiry period				10 years
2014 Convertible Notes
Debt Instrument [Line Items]
Convertible promissory note , interest rate					10.00%
Warrant coverage percentage of notes					100.00%
Fair value of warrants attached to convertible promissory note					4,454,397
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs					6,121,533
Amortization of debt discount	2,682,285
Conversion of preferred stock warrants into common stock			1,116,372
Conversion price per share			$7
Debt instrument, convertible, carrying amount of debt			6,638,645
Accrued interest			314,210
Loss on extinguishment of convertible notes			4,525,075
Common Stock to be issued up on exercise of warrants			750,000
Class of warrant or right, exercise price of warrants or rights			$10
Convertible notes payable					7,500,000
Debt instrument, maturity date					31-Jan-15
Debt issuance costs					1,928,265
Fair value of warrants issued for debt issuance costs					876,778
Amortization of debt issuance costs	844,912
2014 Convertible Notes \| Exchange Traded Options
Debt Instrument [Line Items]
Fair value put option embedded in convertible promissory note					$1,667,136
2014 Convertible Notes \| IPO
Debt Instrument [Line Items]
Price per share of common stock as a percentage IPO price					70.00%
2014 Convertible Notes \| Warrants to Purchase Convertible Preferred Stock \| Equity
Debt Instrument [Line Items]
Debt instrument, expiry period					5 years

Redeemable_Convertible_Preferr2

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Additional Information (Details) (USD $)	12 Months Ended			0 Months Ended	2 Months Ended	3 Months Ended	1 Months Ended					6 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 08, 2014	Apr. 30, 2009	Sep. 30, 2007	31-May-09	Jan. 31, 2010	Sep. 30, 2004	Oct. 31, 2003	Jun. 30, 2005	Jun. 30, 2005	Apr. 30, 2014	Dec. 31, 2010	Jun. 30, 2003
Class Of Stock [Line Items]
Proceeds from exercise of warrants			$3,659
Preferred stock, shares authorized	5,000,000	5,000,000		5,000,000
Preferred stock, par value	$0.00	$0.00		$0.00
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Net income (loss)	-16,260,926	9,476,699	-2,014,744
Research and development expense	7,213,416	10,884,628	11,734,551
General and administrative	4,276,918	3,174,769	5,948,066
Warrant extended term period	5 years
Fair value of warrants issued for debt issuance costs	876,778
Common stock, shares authorized	100,000,000	100,000,000		100,000,000
Common stock, par value	$0.00	$0.00		$0.00
Common stock, shares issued	5,751,574	92,812
Common stock, shares outstanding	5,751,574	92,812
Common stock issuable upon exercise of outstanding warrants	927,069
2014 Notes Warrants
Class Of Stock [Line Items]
Fair value assumptions, warrants	4,454,397
Convertible notes payable	7,500,000
Private placement
Class Of Stock [Line Items]
Risk free interest rate	10.00%
Fair value assumptions, warrants	750,000
Warrant holders
Class Of Stock [Line Items]
Risk free interest rate	10.00%
Fair value assumptions, warrants	750,000
2013 Notes
Class Of Stock [Line Items]
Conversion price per share				$8
Class of warrant or right, exercise price of warrants or rights				$10
Common Stock to be issued up on exercise of warrants				12,373
2014 EIP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans, increase description	EIP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the lesser of 4% of the total number shares of our common stock outstanding on the immediately preceding December 31, or a lesser amount of shares determined by our Board of Directors.
Percentage increase in common stock outstanding	4.00%
Options to Purchase Common Stock
Class Of Stock [Line Items]
Weighted average grant date fair value of options granted	$11.66		$13.55
Total grant date fair value of options vested	72,095	193,828	308,803
Difference between the aggregate exercise price and aggregate fair value price	60,940	1,560	139,620
Intrinsic value of options outstanding	286,299	1,703,515
Intrinsic value of options exercisable	286,299	1,696,012
Company had unrecognized stock based compensation	79,145	60,510
Non-vested stock options, estimated weighted average period	2 years 2 months 12 days	1 year 9 months 18 days
Net income (loss)	48,878	209,715	369,180
Research and development expense	8,919	47,082	143,169
General and administrative	39,959	162,633	226,011
Options to Purchase Common Stock \| 2014 ESPP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans													201,163
Share of common stock reserved for issuance under plans, increase description	ESPP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the least of (i) 1% of the total number of shares of our common stock outstanding on the immediately preceding December 31; (ii) 402,326 shares of common stock; or (iii) a lesser amount of shares determined by our Board of Directors.
Percentage increase in common stock outstanding	1.00%
Increase in shares of common stock	402,326
Options to Purchase Common Stock \| 2014 ESPP \| Evergreen Provision \| Minimum
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans	258,678
Options to Purchase Common Stock \| 2014 EIP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans	601,313
Share of common stock reserved for issuance under plans													393,358
Shares authorized	841,580
Options to Purchase Common Stock \| 2014 EIP \| Evergreen Provision \| Maximum
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans	1,071,642
January 2015 \| Options to Purchase Common Stock \| 2014 ESPP \| Evergreen Provision
Class Of Stock [Line Items]
Increase in shares of common stock	57,515
January 2015 \| Options to Purchase Common Stock \| 2014 EIP \| Evergreen Provision
Class Of Stock [Line Items]
Increase in shares of common stock	230,062
Warrant
Class Of Stock [Line Items]
Expected term				9 years 4 months 24 days
Fair value assumptions, warrants		106,087		104,055
Warrants expire from the date of issuance		10 years
Expected volatility		85.17%		91.00%
Risk-free interest rate		2.67%		2.60%
Warrant \| 2013 Notes
Class Of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights				$10
Common Stock to be issued up on exercise of warrants				12,373
Series C Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, issued						28,482,897
Convertible preferred stock, par value						$1.45
Redeemable, convertible preferred stock, conversion ratio						0.3139
Redeemable, convertible preferred stock redemption percentage						25.00%
Preferred stock, redemption terms	In the event of a liquidation event, holders of Series C preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends.
Redeemable, convertible preferred stock, accrued unpaid dividend per annum						7.00%
Unsecured convertible notes, issued					2,999,989
Unsecured convertible notes, interest rate					8.00%
Unsecured notes converted into preferred stock					2,632,210
Conversion price per share					$1.16
Number of shares of preferred stock purchased by warrant					622,826
Class of warrant or right, exercise price of warrants or rights			$1.45		$1.45
Warrants estimated value					603,767
Number of warrants exercised			158,129
Warrants exercised for preferred stock			29,432
Warrants issued to purchase shares of preferred stock			2,532
Proceeds from exercise of warrants			3,659
Series C Redeemable Convertible Preferred Stock \| Warrant
Class Of Stock [Line Items]
Expected term					10 years
Expected volatility rate					87.50%
Risk free interest rate					2.87%
Series D Redeemable, Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, issued							8,650,519
Convertible preferred stock, par value							$1.16
Redeemable, convertible preferred stock, conversion ratio							31.39
Preferred stock, redemption terms	In the event of a liquidation event, holders of Series D preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends.
Class of warrant or right, exercise price of warrants or rights							$1.45
Warrants estimated value							2,052,662
Warrants issued to purchase shares of preferred stock							2,076,125
Redeemable, convertible preferred stock							10,000,000
Series D Redeemable, Convertible Preferred Stock \| January 2015
Class Of Stock [Line Items]
Redeemable, convertible preferred stock redemption percentage							25.00%
Redeemable, convertible preferred stock, accrued unpaid dividend per annum							7.00%
Series D Redeemable, Convertible Preferred Stock \| Warrant
Class Of Stock [Line Items]
Expected term							10 years
Expected volatility rate							90.50%
Risk free interest rate							3.29%
Series E Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, issued								11,665,019
Convertible preferred stock, par value								$1.54
Redeemable, convertible preferred stock, conversion ratio								31.39
Preferred stock, redemption terms	In the event of a liquidation event, holders of Series E preferred stock were entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends.
Redeemable, convertible preferred stock								17,999,124
Series E Redeemable Convertible Preferred Stock \| January 2015
Class Of Stock [Line Items]
Redeemable, convertible preferred stock redemption percentage								25.00%
Redeemable, convertible preferred stock, accrued unpaid dividend per annum								7.00%
Series A Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Convertible preferred stock, issued									2,399,999						3,999,999
Convertible preferred stock, par value									$1.25						$1.25
Preferred stock, redemption terms	In the event of a liquidation event, holders of Series A preferred stock shall be entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends.
Class of warrant or right, exercise price of warrants or rights								$1.25
Number of warrants exercised														8,000
Proceeds from exercise of warrants								10,000
Conversion of promissory notes to convertible preferred stock value										100,000
Aggregate accrued interest										1,532
Redeemable, convertible preferred stock, dividend percentage per annum									7.00%
Series A Redeemable Convertible Preferred Stock \| January 2015
Class Of Stock [Line Items]
Redeemable, convertible preferred stock redemption percentage									25.00%
Redeemable, convertible preferred stock, accrued unpaid dividend per annum									7.00%
Series B Redeemable Convertible Preferred Stock
Class Of Stock [Line Items]
Redeemable, convertible preferred stock, conversion ratio												31.39
Preferred stock, redemption terms	In the event of a liquidation event, holders of Series B preferred stock shall be entitled to receive the amount of the original purchase price, plus 7% per annum compounded annually plus accrued but unpaid dividends.
Conversion of promissory notes to convertible preferred stock value											2,750,000
Aggregate accrued interest											$50,342
Series B Redeemable Convertible Preferred Stock \| January 2015
Class Of Stock [Line Items]
Redeemable, convertible preferred stock redemption percentage											25.00%	25.00%
Redeemable, convertible preferred stock, accrued unpaid dividend per annum												7.00%

Redeemable_Convertible_Preferr3

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Series B Preferred Stock For Cash and Convertible Promissory Notes Payable (Details) (Series B Redeemable Convertible Preferred Stock, USD $)	Sep. 30, 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	$38,400,003
Conversion of preferred stock to common stock	28,699,551
Initial Closing \| June 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	25,050,000
Conversion of preferred stock to common stock	18,721,973
Second Closing \| July 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	3,500,001
Conversion of preferred stock to common stock	2,615,845
Third Closing \| August 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	4,750,000
Conversion of preferred stock to common stock	3,550,073
Fourth Closing \| September 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	1,000,000
Conversion of preferred stock to common stock	747,384
Fifth Closing \| September 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	2,000,000
Conversion of preferred stock to common stock	1,494,768
Sixth Closing \| October 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	1,000,001
Conversion of preferred stock to common stock	747,385
Final Closing \| December 2005
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Convertible Preferred Stock, Amount	$1,100,001
Conversion of preferred stock to common stock	822,123

Redeemable_Convertible_Preferr4

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees (Details) (Employee Stock Option)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate	1.82%	1.30%
Expected life (in years)	6 years
Expected volatility	95.70%
Expected volatility, minimum		90.90%
Expected volatility, maximum		91.20%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)		5 years 9 months 18 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)		6 years

Redeemable_Convertible_Preferr5

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Non-employees (Details) (Nonemployee Stock Option)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Nonemployee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	2.80%	1.80%	1.40%
Risk-free interest rate, maximum	3.00%	2.70%	2.20%
Expected life (in years)	10 years	10 years	10 years
Expected volatility, minimum	85.20%	82.60%	83.30%
Expected volatility, maximum	85.40%	85.10%	85.20%

Redeemable_Convertible_Preferr6

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Summary of Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity [Abstract]
Number of common stock options, Outstanding at beginning of period	229,494	376,880	362,274
Number of common stock options, Granted	7,279		27,105
Number of common stock options, Exercised	-8,009	-382	-4,566
Number of common stock options, Canceled	-9,584	-147,004	-7,933
Number of common stock options, Outstanding end of period	219,180	229,494	376,880
Number of common stock options, Exercisable at end of period	207,958
Weighted average exercise price, Outstanding at beginning of period	$7.90	$7.87	$7.08
Weighted average exercise price, Granted	$15.10		$18.24
Weighted average exercise price, Exercised	$4.73	$4.73	$4.73
Weighted average exercise price, Canceled	$5.86	$7.82	$9.15
Weighted average exercise price, Outstanding at end of period	$8.35	$7.90	$7.87
Weighted average exercise price, Exercisable at end of period	$7.92
Weighted average remaining contractual term (years), Outstanding at end of period	3 years 9 months 18 days
Weighted average remaining contractual term (years), Exercisable at end of period	3 years 7 months 6 days

Redeemable_Convertible_Preferr7

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Exercisable and Outstanding Stock Options and Warrants Issued to Employees, Directors, and Consultants by Exercise Prices (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options outstanding	219,180	229,494	376,880	362,274
Common stock options outstanding, Weighted average remaining contractual life (years)	3 years 9 months 18 days
Common stock options exercisable	207,958
Common stock options exercisable, Weighted average exercise price	$7.92
4.73
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$4.73
Common stock options outstanding	56,175
Common stock options outstanding, Weighted average remaining contractual life (years)	1 year 4 months 2 days
Common stock options exercisable	56,175
Common stock options exercisable, Weighted average exercise price	$4.73
5.04
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$5.04
Common stock options outstanding	4,820
Common stock options outstanding, Weighted average remaining contractual life (years)	2 years 4 months 2 days
Common stock options exercisable	4,820
Common stock options exercisable, Weighted average exercise price	$5.04
5.98
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$5.98
Common stock options outstanding	67,575
Common stock options outstanding, Weighted average remaining contractual life (years)	3 years 2 months 1 day
Common stock options exercisable	67,575
Common stock options exercisable, Weighted average exercise price	$5.98
6.93
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$6.93
Common stock options outstanding	14,882
Common stock options outstanding, Weighted average remaining contractual life (years)	4 years 3 months
Common stock options exercisable	14,882
Common stock options exercisable, Weighted average exercise price	$6.93
8.52
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$8.52
Common stock options outstanding	6,971
Common stock options outstanding, Weighted average remaining contractual life (years)	4 years 9 months
Common stock options exercisable	6,971
Common stock options exercisable, Weighted average exercise price	$8.52
10.07
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$10.07
Common stock options outstanding	2,814
Common stock options outstanding, Weighted average remaining contractual life (years)	6 years 2 months 16 days
Common stock options exercisable	2,814
Common stock options exercisable, Weighted average exercise price	$10.07
12.56
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$12.56
Common stock options outstanding	41,464
Common stock options outstanding, Weighted average remaining contractual life (years)	5 years 7 months 10 days
Common stock options exercisable	41,464
Common stock options exercisable, Weighted average exercise price	$12.56
15.1
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$15.10
Common stock options outstanding	7,279
Common stock options outstanding, Weighted average remaining contractual life (years)	9 years 2 months 12 days
Common stock options exercisable, Weighted average exercise price	$15.10
18.24
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$18.24
Common stock options outstanding	17,200
Common stock options outstanding, Weighted average remaining contractual life (years)	7 years 2 months 27 days
Common stock options exercisable	13,257
Common stock options exercisable, Weighted average exercise price	$18.24

Redeemable_Convertible_Preferr8

Redeemable, Convertible Preferred Stock and Stockholders' Equity - Summary of Preferred Stock Warrants Oustanding, Fair Value of Warrants And Assumptions Used to Estimate Fair Value (Details) (Black-Scholes Assumptions, USD $)	0 Months Ended	12 Months Ended
	Jul. 08, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Total Long-term
Black-Scholes assumptions
Estimated fair value of vested warrants	$309,879		$1,458,841	$3,301,411
Total Short-term
Black-Scholes assumptions
Estimated fair value of vested warrants			13
Warrants Issued With 2004 Financing Agreement
Class Of Stock [Line Items]
Issue date		2004-03
Redeemable and convertible preferred stock underlying the warrant		Series A
Number of warrants issued		22,000
Class of warrant or right, exercise price of warrants or rights		$1.25
Black-Scholes assumptions
Expected term			2 months 12 days	1 year 2 months 12 days
Expected volatility rate			61.00%	83.00%
Risk free interest rate			0.07%	0.16%
Number of warrants remaining outstanding			22,000	22,000
Estimated fair value of vested warrants			13	2,837
Warrants Issued With 2005 Convertible Promissory Notes
Class Of Stock [Line Items]
Issue date		2005-06
Redeemable and convertible preferred stock underlying the warrant		Series B
Number of warrants issued		411,060
Class of warrant or right, exercise price of warrants or rights		$1.34
Black-Scholes assumptions
Expected term	1 year		1 year 6 months	2 years 6 months
Expected volatility rate	70.50%		66.50%	86.50%
Risk free interest rate	0.12%		0.24%	0.31%
Number of warrants remaining outstanding	411,060		411,060	411,060
Estimated fair value of vested warrants	1,395		28,098	100,270
Warrants Issued With 2006 Financing Agreement
Class Of Stock [Line Items]
Issue date		2006-04
Redeemable and convertible preferred stock underlying the warrant		Series B
Number of warrants issued		179,372
Class of warrant or right, exercise price of warrants or rights		$1.34
Black-Scholes assumptions
Expected term	1 year 9 months 18 days		2 years 3 months 18 days	3 years 3 months 18 days
Expected volatility rate	68.50%		84.50%	85.50%
Risk free interest rate	0.33%		0.52%	0.35%
Number of warrants remaining outstanding	179,372		179,372	179,372
Estimated fair value of vested warrants	2,539		32,735	52,680
Warrants Issued With 2009 Convertible Promissory Notes
Class Of Stock [Line Items]
Issue date		2009-05
Redeemable and convertible preferred stock underlying the warrant		Series C
Number of warrants issued		622,826
Class of warrant or right, exercise price of warrants or rights		$1.45
Black-Scholes assumptions
Expected term	4 years 10 months 24 days		5 years 4 months 24 days	6 years 4 months 24 days
Expected volatility rate	82.00%		97.00%	92.00%
Risk free interest rate	1.52%		1.58%	0.92%
Number of warrants remaining outstanding	620,294		620,294	620,294
Estimated fair value of vested warrants	70,381		321,603	723,631
Warrants Issued With 2009 Issuance of Series D Preferred Stock
Class Of Stock [Line Items]
Issue date		2009-05
Redeemable and convertible preferred stock underlying the warrant		Series C
Number of warrants issued		2,076,125
Class of warrant or right, exercise price of warrants or rights		$1.45
Black-Scholes assumptions
Expected term	4 years 10 months 24 days		5 years 4 months 24 days	6 years 4 months 24 days
Expected volatility rate	82.00%		97.00%	92.00%
Risk free interest rate	1.52%		1.58%	0.92%
Number of warrants remaining outstanding	2,076,125		2,076,125	2,076,125
Estimated fair value of vested warrants	$235,564		$1,076,405	$2,421,993

Deferred_Revenue_Components_of

Deferred Revenue - Components of Deferred Revenue (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$10,784,069	$14,413,875
Less: current portion	-3,340,571	-3,756,899
Deferred revenue, long-term	7,443,498	10,656,976
Celgene
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	10,751,120	14,169,164
Gilead
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$32,949	$244,711

Deferred_Revenue_Additional_In

Deferred Revenue - Additional Information (Details) (USD $)	12 Months Ended			1 Months Ended				3 Months Ended	36 Months Ended	1 Months Ended
Deferred Revenue - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2013	Apr. 30, 2012	Oct. 31, 2011	31-May-09	Dec. 31, 2013	Apr. 30, 2012	Nov. 30, 2011
Deferred Revenue Arrangement [Line Items]
Collaboration license and services	$4,426,561	$16,350,132	$12,641,606
Costs of collaboration license and services	3,452,392	5,856,013	10,033,040
Milestones		3,000,000	2,000,000
Manufacturing services	1,539,820	3,168,237
Costs of manufacturing services	1,539,820	3,168,237
Celgene
Deferred Revenue Arrangement [Line Items]
Collaboration and Option agreement date	31-May-09
Number of oncology products	4
Upfront payment received				9,000,000
Initial nonrefundable payment received					300,000	1,000,000	30,000,000
Costs of collaboration license and services	2,563,409	2,515,055	8,184,806
Celgene \| Undelivered Items
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized				233,119
Celgene \| License
Deferred Revenue Arrangement [Line Items]
Collaboration license and services								8,766,881
License and service revenue recognized	138,975	8,766,881
Celgene \| Research and Development
Deferred Revenue Arrangement [Line Items]
License and service revenue recognized	3,279,069	3,307,338	3,622,764
Celgene \| May 2009 to April 2012
Deferred Revenue Arrangement [Line Items]
Upfront payment received									31,300,000
Celgene \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	60,000,000
Celgene \| Development And Regulatory Milestones \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	101,000,000
Celgene \| GI-6200 \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	60,000,000
Celgene \| GI-6200 \| Development And Regulatory Milestones
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	85,000,000
Celgene \| GI-6301 \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	60,000,000
Celgene \| GI-6301 \| Development And Regulatory Milestones
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	85,000,000
Gilead
Deferred Revenue Arrangement [Line Items]
Upfront payment received										10,000,000
Costs of collaboration license and services	817,103	3,340,958	1,848,234
Milestones		3,000,000	2,000,000
Manufacturing services	1,539,820	3,168,237
Costs of manufacturing services	1,539,820	3,168,237
Gilead \| License
Deferred Revenue Arrangement [Line Items]
License and service revenue recognized	221,392	4,039,538	9,018,842
Gilead \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	40,000,000
Gilead \| Development And Regulatory Milestones \| Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	$130,000,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Details) (USD $)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments And Contingencies [Line Items]
Lease agreement amendment extended term	5 years
Rental Expense		$598,315	$448,664	$398,069
University of Colorado
Commitments And Contingencies [Line Items]
Development milestone payments		150,000
Milestone payment due		5,000	450,000	325,000
National Institutes Of Health License
Commitments And Contingencies [Line Items]
License termination notice period		60 days
Royalty payment		300,000	300,000	250,000
National Institutes Of Health License \| Maximum
Commitments And Contingencies [Line Items]
Annual royalty payment		300,000
National Institutes of Health VirusPlus Agreement
Commitments And Contingencies [Line Items]
Royalty advances		500,000
National Institutes of Health CEA Agreement
Commitments And Contingencies [Line Items]
Royalty advances		745,000
National Institutes of Health Brachyury Agreement
Commitments And Contingencies [Line Items]
Royalty advances		800,000
National Institutes of Health MUC1 Agreement
Commitments And Contingencies [Line Items]
Royalty advances		$500,000

Commitment_and_Contingencies_S

Commitment and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) (USD $)	Dec. 31, 2014
Leases Operating [Abstract]
2015	$595,747
2016	609,339
2017	627,702
2018	646,475
2019	162,798
Total	$2,642,061

Benefit_Plan_Additional_Inform

Benefit Plan - Additional Information (Details)	12 Months Ended
Benefit Plan - Additional Information (Details)	Dec. 31, 2014
Compensation And Retirement Disclosure [Abstract]
Employees Contribution Plan	60.00%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	12 Months Ended
Income Taxes - Additional Information (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Taxes [Line Items]
Federal income tax provision or benefit	$0		$0
Current state tax provision		115,765
Increase (decrease) in valuation allowance	2,540,162	-2,085,277
Federal and state net operating loss carryforwards	116,200,000
Federal research credit carryforwards	7,000,000
Uncertain tax positions, accrued interest or penalties	$0	$0
Minimum
Income Taxes [Line Items]
Federal and state net operating loss carryforwards expire year	2022
Federal research credit carryforwards expire year	2022
Maximum
Income Taxes [Line Items]
Federal and state net operating loss carryforwards expire year	2034
Federal research credit carryforwards expire year	2034

Income_Taxes_Schedule_of_Effec

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. federal income tax expense at the statutory rate	-34.00%	34.00%	-34.00%
State income taxes, net of federal taxes	-1.40%	4.10%	-7.20%
Available research credits	-2.40%	-9.30%
Effect of permanent differences	22.20%	-5.80%	-27.20%
Change in valuation allowance	15.60%	-21.80%	68.40%
Total	0.00%	1.20%	0.00%

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Components of Deferred Tax Assets [Abstract]
Accrued benefits	$93,380	$99,494
Net operating loss carryforwards	44,142,487	40,636,733
Research credit carryforwards	7,045,830	6,661,348
Deferred revenue	4,138,236	5,295,697
Depreciation of property and equipment	1,351,186	1,532,398
Other	111,250	116,537
Total deferred tax assets	56,882,369	54,342,207
Valuation allowance	-56,882,369	-54,342,207
Deferred tax assets, net of valuation allowance	$0	$0